Alzheimer's Disease: Exploring the Landscape of Cognitive Decline

Rumiana Tenchov, Janet M. Sasso, Qiongqiong Angela Zhou*

CAS, a division of the American Chemical Society, Columbus OH 43210, USA

*Corresponding author: qzhou@cas.org

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired daily functioning. The pathology of AD is marked by the accumulation of amyloid-beta plaques and tau protein tangles in brain, along with neuroinflammation and synaptic dysfunction. Genetic factors, such as mutations in APP, PSEN1, and PSEN2 genes, as well as APOE ε4 allele, contribute to increased risk of acquiring AD. Currently available treatments provide symptomatic relief but do not halt disease progression. Research efforts are focused on developing disease-modifying therapies that target the underlying pathological mechanisms of AD. Advances in identification and validation of reliable biomarkers for AD hold great promise for enhancing early diagnosis, monitoring disease progression, and assessing treatment response in clinical practice, in effort to alleviate the burden of this devastating disease.

In this paper, we analyze data from the CAS Content Collection to summarize the research progress in Alzheimer's disease. We examine the publication landscape in effort to provide insights into current knowledge advances and developments. We also review the most discussed and emerging concepts and assess the strategies to combat the disease. We explore the genetic risk factors, pharmacological targets, and comorbid diseases. Finally, we inspect clinical applications of products against AD with their development pipelines and efforts for drug repurposing. The objective of this review is to provide a broad overview of the evolving landscape of current knowledge regarding AD, to outline challenges, and evaluate growth opportunities to further efforts in combating the disease.

Keywords: Alzheimer's disease; pathogenesis; aging; amyloid-beta plaques; tau protein tangles; protein aggregation; biomarker

Introduction

Alzheimer's disease (AD) is a progressive neurological disorder characterized by cognitive decline, memory loss, and changes in behavior and personality, severe enough to interfere with daily life and activities. Alzheimer's typically begins slowly and worsens over time, eventually leading to severe impairment in memory, reasoning, judgment, and language skills. [1-6]

Alzheimer's disease is associated with abnormal deposits of proteins in the brain, specifically β-amyloid plaques and tau tangles. These deposits disrupt communication between brain cells and lead to their eventual death. [7] Advanced age is the greatest risk factor for Alzheimer's disease, with the majority of cases occurring in individuals over 65. Other risk factors include genetics, family history, and certain lifestyle factors such as cardiovascular health and education level. [8] There is no particular test to conclusively diagnose AD. Diagnosis is typically based on a combination of medical history, cognitive assessments, neurological exams, and ruling out other possible causes of symptoms. [9] While there is no cure for AD, there are medications and non-drug interventions that can help manage symptoms and improve quality of life for patients.

AD can be emotionally and physically challenging for both individuals with the disease and their caregivers. Supportive services such as counseling, support groups, and respite care can be valuable resources for managing the impact of the disease on daily life. [10] Research into AD is intense, with efforts focused on understanding its underlying causes, developing more effective treatments, and ultimately finding a cure. Early detection and intervention are important for maximizing treatment effectiveness and improving outcomes for patients affected by the disease.

In this paper, we analyze data from the CAS Content Collection to summarize the research progress in Alzheimer's disease. We examine the publication landscape in the area in effort to provide insights into current knowledge advances and developments. We review the most discussed and emerging concepts and assess the strategies to combat the disease. We explore the genetic risk factors, pharmacological targets, and comorbid diseases. Finally, we inspect clinical applications of products against AD with their development pipelines and efforts for drug repurposing. The objective of this review is to provide a broad overview of the evolving landscape of current knowledge regarding AD, to outline challenges, and evaluate growth opportunities to further efforts in combating the diseases.

Overview of Alzheimer's disease

Prevalence and impact

The prevalence and impact of AD are significant and continue to grow as populations age. According to the World Health Organization (WHO), around 50 million people worldwide have dementia, and AD accounts for 60-70% of cases. The prevalence of Alzheimer's increases with age, and the majority of cases occur in individuals over 65 years old. As life expectancy increases globally, the number of people living with AD is expected to rise substantially in the coming decades. [11, 12]

AD has a profound impact on individuals, families, and society as a whole. Individuals with Alzheimer's experience a progressive decline in cognitive function, memory loss, and changes

in behavior and personality, leading to a loss of independence and ability to perform daily tasks. Caregivers, typically family members, bear a significant burden in providing care and support for individuals with AD, often leading to emotional, physical, and financial strain. The economic impact of AD is substantial, including direct medical costs for diagnosis, treatment, and long-term care, as well as indirect costs associated with lost productivity and caregiver burden.

Pathogenesis

The pathogenesis of AD involves a complex interplay of genetic, environmental, and age-related factors, leading to progressive neurodegeneration and cognitive decline. [13] One of the defining features of AD is the accumulation of β-amyloid protein fragments in the brain, leading to the formation of insoluble plaques. [14, 15] β-Amyloid is produced from the cleavage of a larger protein called amyloid precursor protein (APP) by enzymes known as β-secretase and γ-secretase. [16] Abnormal processing of APP, along with impaired clearance of β-amyloid from the brain, results in the accumulation of β-amyloid plaques, which are toxic to neurons and disrupt synaptic function (Figure 1A).


Figure 1. (A) Normal and abnormal cleavage of amyloid precursor protein (APP): when cleaved by α-secretase in the middle of the β-amyloid domain (Aβ), it is not amyloidogenic; however, when APP is cleaved by β- and γ-secretase enzymes, neurotoxic Aβ peptides are released, which can accumulate into oligomer aggregates and further form insoluble β-sheet amyloid fibrils triggering local inflammatory response. (B) Formation of neurofibrillary tangles by the tau protein and subsequent neuron death in tauopathies such as Alzheimer's disease. In pathologies, tau becomes hyperphosphorylated and detaches from microtubules, which causes microtubule destabilization; phosphorylated tau aggregates to form neurofibrillary tangles.

3

Another characteristic feature of AD is the abnormal accumulation of tau protein in the form of neurofibrillary tangles within neurons. [17-19] Tau protein plays a crucial role in stabilizing microtubules, which are essential for maintaining the structure and function of neurons. In AD, tau protein becomes hyperphosphorylated, leading to its misfolding and aggregation into neurofibrillary tangles (Figure 1B). These tangles interfere with intracellular transport and contribute to neuronal dysfunction and cell death.

The accumulation of β-amyloid plaques and tau protein tangles disrupts normal neuronal function, leading to synaptic dysfunction and impaired neurotransmission. [20] As the disease progresses, neurons become increasingly vulnerable to damage and eventually undergo cell death, resulting in widespread neuronal loss, particularly in brain regions critical for memory and cognitive function, such as the hippocampus and cerebral cortex. [21]

Neuroinflammation, characterized by the activation of microglia and astrocytes, plays a significant role in the pathogenesis of AD. Chronic inflammation in the brain exacerbates neuronal damage and contributes to disease progression by releasing pro-inflammatory cytokines, reactive oxygen species, and other neurotoxic molecules. [22, 23]

Vascular dysfunction and impaired cerebral blood flow are common features of AD and may contribute to neuronal damage and cognitive decline. Chronic cerebral hypoperfusion, resulting from vascular pathology, can exacerbate β-amyloid deposition and tau pathology and increase the risk of cognitive impairment. [24, 25]

While most cases of AD are sporadic, a small percentage are inherited in an autosomal dominant fashion, known as familial Alzheimer's disease (FAD). [26] Mutations in genes such as amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are associated with early-onset FAD, leading to increased production or altered processing of β-amyloid. [27] The apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (LOAD) and is associated with increased β-amyloid deposition and enhanced risk of developing AD.

Risk factors for cardiovascular disease, such as hypertension, high cholesterol, diabetes, and obesity, are also associated with an increased risk of AD. Regular physical exercise has been shown to have a protective effect against AD and cognitive decline. Some dietary patterns, such as the Mediterranean diet, rich in fruits, vegetables, whole grains, fish, and healthy fats, may lower the risk of AD. Higher levels of education and engagement in mentally stimulating activities throughout life may help reduce the risk of developing AD.

Some environmental factors, such as air pollution, heavy metal exposure, and certain toxins, have been implicated as potential risk factors for AD, although more research is needed to fully understand their impact.

Genetic background

The genetic background of Alzheimer's disease (AD) encompasses both rare familial forms and more common late-onset forms. [28]

4

Familial Alzheimer's disease (FAD) represents a small percentage of Alzheimer's cases and is inherited in an autosomal dominant pattern, meaning that an affected individual has a 50% chance of passing the mutated gene to their offspring. Mutations in three genes have been identified as causative for FAD: (i) Amyloid precursor protein (APP): mutations in the APP gene, located on chromosome 21, tend to inhibit cleavage by α-secretase and facilitate preferential cleavage by β-secretase, which leads to increased production or altered processing of β-amyloid, resulting in the accumulation of amyloid plaques in the brain; (ii) Presenilin 1 (PSEN1): mutations in the PSEN1 gene, located on chromosome 14, are the most common cause of FAD. PSEN1 is a component of the γ-secretase complex involved in the cleavage of amyloid precursor protein (APP), and mutations in PSEN1 enhance cleavage by γ-secretase and lead to increased production of β-amyloid; (iii) Presenilin 2 (PSEN2): mutations in the PSEN2 gene, located on chromosome 1, are less common but can also cause FAD. Like PSEN1, PSEN2 is involved in the processing of APP, enhanced cleavage by γ-secretase, and the production of β-amyloid. [16, 29-31]

Late-onset Alzheimer's disease (LOAD) is the most common form of AD and typically occurs after age of 65. While LOAD has a strong genetic component, it is influenced by multiple genetic and environmental factors. The strongest genetic risk factor for LOAD is the apolipoprotein E (APOE) gene, located on chromosome 19. The APOE gene has three common alleles: ε2, ε3, and ε4. The ε4 allele of APOE is associated with an increased risk of developing AD and a younger age of onset. Individuals who inherit one copy of the APOE ε4 allele have an increased risk, while those who inherit two copies have an even higher risk. In addition to APOE, several other genetic variants have been identified as risk factors for LOAD through genome-wide association studies. These include genes involved in inflammation, cholesterol metabolism, immune response, and synaptic function. While these genetic risk factors increase susceptibility to AD, they do not guarantee that an individual will develop the condition. Environmental factors and gene-environment interactions also play a significant role in disease risk. [32-35]

Symptoms and progression

AD progresses gradually over time, and the symptoms can vary from person to person. One of the most common early signs is difficulty remembering recent events, conversations, or information. Individuals may have trouble with tasks that require planning, decision-making, and problem-solving. They may become disoriented, especially in unfamiliar environments, and have difficulty following directions or understanding the passage of time. They may have trouble finding the right words or understanding spoken or written language. Changes in mood, such as depression, anxiety, or apathy, and shifts in personality traits may occur. [36-40]

As AD progresses, memory loss becomes more severe and may include forgetting the names of close family members or important personal information. Language difficulties may worsen, making it increasingly difficult to engage in conversations or express thoughts. Individuals may have difficulty making decisions or solving problems, and they may exhibit poor judgment in everyday situations. Behavioral symptoms such

as agitation, aggression, wandering, or social withdrawal may become more pronounced. In the later stages of AD, individuals may experience physical symptoms such as difficulty swallowing, walking, or performing basic self-care tasks. As the disease progresses, individuals become increasingly dependent on others for assistance with activities of daily living.

In the advanced stages of AD, individuals may lose the ability to communicate verbally, recognize loved ones, or control movement. They may require round-the-clock care in a residential facility or at home with the assistance of caregivers. Physical complications such as infections, falls, and malnutrition become more common, contributing to further decline in health.

Diagnosis

Diagnosing AD involves a comprehensive assessment by healthcare professionals, including medical history, physical examination, cognitive assessments, and imaging tests. Cognitive tests are used to evaluate memory, attention, language, problem-solving, and other cognitive functions. These assessments may include standardized tests such as the Mini-Mental State Examination (MMSE) or the Montreal Cognitive Assessment (MoCA). [41-43] The healthcare provider may also administer more in-depth neuropsychological testing to assess specific cognitive domains and identify patterns of impairment.

A neurological examination may be performed to assess for signs of neurological dysfunction, such as abnormal reflexes, muscle weakness, or coordination problems. Imaging tests such as magnetic resonance imaging (MRI) or positron emission tomography (PET) scans may be used to rule out other possible causes of cognitive impairment, such as stroke, tumor, or hydrocephalus. These imaging studies can also help visualize changes in the brain associated with AD, such as atrophy (shrinkage) of brain regions involved in memory and cognition or the presence of β-amyloid plaques and tau tangles. Blood tests may be performed to rule out other medical conditions that can cause cognitive impairment, such as thyroid dysfunction, vitamin deficiencies, or infections. Cerebrospinal fluid (CSF) analysis may be considered in some cases to measure levels of β-amyloid and tau proteins, which can be indicative of AD pathology. In addition, non-invasive diagnostic tests are being considered as a part to the comprehensive AD assessment. One such test, PrecivityAD2 is a clinical care assay that measures both plasma amyloid beta and tau peptide concentrations. [44, 45] Other assays utilizing not only blood, but saliva and urine are currently being researched. [46, 47]

Diagnosis of AD is typically based on clinical criteria established by organizations such as the National Institute on Aging and the Alzheimer's Association (NIA-AA) or the International Working Group (IWG) for AD. [48-50] These criteria consider the presence and pattern of cognitive symptoms, the progression of symptoms over time, and the exclusion of other possible causes of dementia.

6

Treatment and management

Treatment and management of AD aim to alleviate symptoms, slow down the progression of the disease, and improve the quality of life for individuals affected by the condition. While there is currently no cure for AD, various interventions can help manage symptoms and support overall well-being. [51-54]

Medications such as donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne) are cholinesterase Inhibitors commonly prescribed to treat cognitive symptoms associated with AD. [55] These drugs work by increasing levels of acetylcholine, a neurotransmitter involved in memory and learning, in the brain. [56, 57] Memantine (Namenda) is another medication approved for the treatment of AD. It works by regulating the activity of glutamate, another neurotransmitter involved in learning and memory. These medications may help improve cognitive function, behavior, and daily functioning in some individuals with AD. For more information on AD medications, see Table 1 and Figure 10 in the Landscape analysis section further in the text.

Engaging in mentally stimulating activities may help maintain cognitive function and slow down cognitive decline. Regular physical activity has been shown to have beneficial effects on cognition and overall health in individuals with AD. Eating a balanced diet can support overall brain health and well-being. Addressing sleep disturbances and establishing healthy sleep habits can help improve cognitive function and mood in individuals with AD. [58-60]

Behavioral interventions such as cognitive-behavioral therapy (CBT) or behavior modification techniques may help manage challenging behaviors such as agitation, aggression, or wandering. [61-63] Counseling, support groups, and other psychosocial interventions can provide emotional support, education, and coping strategies for individuals with AD and their caregivers. [64, 65]

Landscape analysis of Alzheimer's disease research

Journal publication and patent trends (CAS Content Collection data)

The CAS Content Collection [66] is the largest human-compiled collection of published scientific information, which represents a valuable resource to access and keep up to date on the scientific literature all over the world across disciplines including chemistry, biomedical sciences, engineering, materials science, agricultural science, and many more, thus allowing quantitative analysis of global research publications across various parameters including time, geography, scientific area, medical application, disease, and chemical composition. Currently, there are over 300,000 scientific publications (mainly journal articles and patents) in the CAS Content Collection related to the AD, including over 250,000 articles in scientific journals and nearly 50,000 patents. There has been a steady growth of these documents over the last three decades, with an >30% increase in the last three years (2021-2023) (Figure 2A). The journal articles largely dominate, showcasing the intense research in the area. The relative growth in the number of documents related to the AD as well as the journal/patent number ratio virtually coincides with that for the overall class of neurodegenerative diseases during the last two decades (Figure 2B) which is understandable since AD is by far the most prevalent and most

widely explored disease in that class of diseases. The high journal/patent number ratio with regards to the AD research in the 1990s reflect the initial period of knowledge accumulation preceding the subsequent opportunities for commercialization.


Figure 2. (A) Yearly trend of the number of documents (journal articles and patents) in the CAS Content Collection™ related to the AD; (B) comparison between relative growth in the number of documents related to the AD (dark blue bars) and all neurodegenerative diseases (light blue bars); orange and yellow lines compare the journal/patent ratio for the AD and all neurodegenerative diseases, respectively.

USA, China, Japan, Germany, and South Korea are the leaders with respect to the number of published journal articles and patents related to AD research (Figure 3). The Alzheimer's Disease Neuroimaging Initiative, University of California, Harvard Medical School, and the Chinese Academy of Sciences are the leaders with respect to the number of published journal articles related to the AD (Figure 4A). Patenting activity is dominated by corporate players as compared to academics (Figure 4B,C).   F. Hoffmann-La Roche, Merck, Pfizer, and AstraZeneca have the highest number of patent applications among the companies (Figure 4B), while University of California, Centre national de la recherche scientifique (CNRS, France), and Korea Institute of Science & Technology lead among the non-commercial organizations (Figure 4C). The most patent applications have been filed at the World Intellectual Property Organization (WIPO) followed by the US and China patent offices (Figure 5). *Journal of Alzheimer's Disease* is a distinct leader with respect to the number of published articles related to Alzheimer's disease research, followed by *Neurobiology of Aging, Neurology*, and *PLoS One* (Figure 6). With respect to the substance classes explored in the AD-related documents in CAS Content Collection, the largest part belong to the organic & inorganic small molecules (Figure 7).

8

Figure 3. Top countries/regions with respect to the numbers of AD-related journal articles (inner pie chart) and patents (outer donut chart) in the CAS Content Collection.

A Journal articles

Organization	Country	Number of articles
Alzheimer's Disease Neuroimaging Initiative	USA	2,689
University of California	USA	1,360
Harvard Medical School	USA	804
Chinese Academy of Sciences	China	716
University of Kentucky	USA	700
Huazhong University of Science & Technology	China	601
Washington University	USA	550
Case Western Reserve University	USA	516
University of Cambridge	UK	509
Karolinska Institutet	Sweden	495
Capital Medical University	China	475
Fudan University	China	468
University of Pennsylvania	USA	468
McGill University	Canada	462
Mayo Clinic	USA	413
Central South University	China	405
University of Toronto	Canada	401
University of Southern California	USA	387
Russian Academy of Sciences	Russia	382
Massachusetts General Hospital	USA	381
Kyoto University	Japan	375
University of British Columbia	Canada	342
China Pharmaceutical University	China	339
Columbia University	USA	331
University of Melbourne	Australia	330

B Patents

Organization (commercial)	Country	Number of patents
F. Hoffmann-La Roche	Switzerland	735
Merck & Co	USA	505
Pfizer	USA	402
AstraZeneca	UK	300
Janssen Pharmaceutica	Belgium	268
Wyeth Pharmaceuticals	USA	263
Neurosearch	Denmark	247
Novartis	Switzerland	211
Takeda Chemical Industries	Japan	208
Bristol-Myers Squibb	USA	206
Vertex Pharmaceuticals	USA	181
Eli Lilly	USA	174
Abbott Laboratories	USA	171
H. Lundbeck	Denmark	164
Sanofi-Aventis	France	148
Elan Pharmaceuticals	Ireland	146
Schering	Germany	140
Taisho Pharmaceutical	Japan	137
Genentech	USA	136
Smithkline Beecham	UK	136
Glaxo Group	UK	117
Amgen	USA	110
Les Laboratoires Servier	France	106
Boehringer Ingelheim	Germany	95
Allergan	Ireland	85
Pharmacia & Upjohn	Sweden	85

C

Organization (non-commercial)	Country	Number of patents
University of California	USA	448
CNRS	France	222
Korea Inst. Sci & Technol	South Korea	169
General Hospital Corporation	USA	168
China Pharmaceutical University	China	166
Harvard College	USA	130
Shanghai Institute of Materia Medica	China	120
University of South Florida	USA	120
Massachusetts Institute of Technology	USA	119
Johns Hopkins University	USA	114
Sun Yat-Sen University	China	113
Sichuan University	China	99
Seoul National University	South Korea	94
Washington University	USA	90
Duke University	USA	88
New York University	USA	86
Suven Life Sciences	India	86
Leland Stanford Junior University	USA	86
Fudan University	China	84
Vanderbilt University	USA	83
Brigham and Women's Hospital	USA	81
Jinan University	China	79
Emory University	USA	77
Zhejiang University	China	76
Scripps Research Institute	USA	75
INSERM	France	74

Figure 4. Leading organizations publishing documents related to AD as found in the CAS Content Collection: (A) journal articles; (B) patents by commercial organizations; (C) patents by non-commercial organizations.

Figure 5. Distribution of patents related to AD with respect to patent offices they have been filed at (WIPO: World Intellectual Property Organization; EPO: European Patent Office).


Figure 6. Leading scientific journals publishing articles related to AD as found in the CAS Content Collection.

Figure 7. Distribution of the major substance classes between the documents related to the AD research.

Aging and β-amyloid are the most widely explored concepts in AD research

We further explored distribution of the Alzheimer's disease-related concepts in the published documents (journals and patents) and their annual trends (Figure 8). Aging and β-amyloid are the most widely explored concepts (Figure 8A). This finding is well rationalized. Indeed, aging is a leading risk factor for Alzheimer disease. [12, 67, 68] Biological processes altered with aging, which have been implicated in AD. It has been explicated that the pathogenesis of AD and other neurodegenerative diseases is associated with the major hallmarks of ageing: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, stem cell exhaustion and altered intercellular communication. [69-72]

According to the existing hypotheses, the accumulation of toxic amyloid β-protein (Aβ) in the central nervous system is the major pathophysiological feature and the basis of AD. [73-75] Extracellular abnormalities of Aβ levels in the brain may result in the accumulation of Aβ, forming a structure rich in β-sheet structures. Upon forming oligomers, they recombine into fibrils to form amyloid plaques (Figure 1).

11

Figure 8. (A) Key concepts explored in the scientific publications related to AD as found in the CAS Content Collection, with a number of documents indicated; (B) Yearly growth of the number of documents (journal articles and patents) exploring certain essential AD-related concepts.

Biomarkers are the fastest growing concept related to AD

Figure 8B illustrates the annual trends in some key concepts during the last five years (2019−2023). The biomarker concept appears as the fastest growing one. Biomarkers are measurable indicators or characteristics that can provide information about the presence, progression, or risk of developing the disease. [76, 77] They play a crucial role in diagnosing, monitoring disease progression, assessing treatment response, and facilitating research into the underlying mechanisms of disease. For example, the levels of an amyloid-beta peptide, Aβ42, a fragment of amyloid-beta protein, in the cerebrospinal fluid (CSF) are typically decreased in individuals with AD compared to healthy individuals. [78-81] Aβ42 is known to aggregate and form plaques in the brain, a hallmark pathology of Alzheimer's. CSF levels of tau proteins, particularly phosphorylated tau, are elevated in AD patients. [80-82] Tau proteins are involved in microtubule stabilization, and their abnormal phosphorylation leads to neurofibrillary tangle formation, another pathological feature of AD. [17, 83]

Overall, biomarkers from cerebrospinal fluid (CSF) and from blood plasma including amyloid peptides and phosphorylated tau are used as AD biomarkers in clinic. [84-87] The procedure for detection of CSF-based biomarkers is intrusive, it requires a lumbar puncture. In contrast, blood tests for AD biomarkers offer the potential for non-invasive, cost-effective screening and monitoring of disease progression, hence, blood-based biomarkers are highly preferred and are currently being actively researched and developed. [88-90] These include measures of amyloid-beta, tau, neurofilament light

chain, and other proteins associated with AD pathology (Figure 9). Genetic variants associated with AD, such as mutations in the amyloid precursor protein, presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes, can serve as biomarkers for increased risk of developing familial forms of AD. [27, 91] The apolipoprotein E (APOE) gene, particularly the ε4 allele, is a well-established genetic risk factor for late-onset AD. APOE genotyping can help identify individuals at higher risk of developing AD. [92, 93]

Positron emission tomography (PET) imaging using radiotracers that bind to amyloid plaques allows for the visualization and quantification of amyloid deposition in the brain. [94-96] Amyloid PET scans can help confirm the presence of AD pathology in individuals with cognitive impairment. PET imaging using radiotracers specific to tau aggregates enables the visualization of neurofibrillary tangles in the brain, providing insights into the spread and distribution of tau pathology in AD. Magnetic resonance imaging (MRI) techniques can detect structural changes, such as hippocampal atrophy and cortical thinning, as well as functional alterations, such as changes in brain connectivity, associated with AD. [97-99]

Biomarkers of neuroinflammation, such as markers of microglial activation and inflammatory cytokines, are being investigated for their potential role in AD pathogenesis and progression. [100-102] Biomarkers of neuronal injury and degeneration, such as neurofilament light chain (NFL) levels in CSF or blood, can indicate ongoing neurodegenerative processes in AD. [103, 104] The identification and validation of reliable biomarkers for AD hold great promise for improving early diagnosis, monitoring disease progression, and assessing treatment response in clinical practice. Ongoing research efforts continue to advance our understanding of Alzheimer's biomarkers and their clinical utility in the management of this devastating neurodegenerative disorder. Exemplary AD biomarkers are illustrated in Figure 9.


Figure 9. AD biomarkers as represented in the CAS Content Collection

A large assortment of comorbid diseases is associated with AD. [105] There is evidence that chronic diseases, including diabetes, cardiovascular disease, depression, and inflammatory bowel disease, may be associated with enhanced risk of AD. Disruption in certain shared biological pathways has been suggested as the underlying mechanism for the relationship between AD and these diseases. Particularly, inflammation is a common dysregulated pathway shared by most of the diseases associated with AD. We examined the co-occurrence of certain diseases with AD as reflected by the co-occurrence of the respective concepts in the documents of the CAS Content Collection (Figure 10A). Dementia and inflammation are between the expected co-occurrences. With respect to cancer, inverse occurrence of cancer and Alzheimer disease has been reported: patients with dominant cancer had a 43% lower risk of developing AD, and those with prevalent AD had a 69% lower risk of being diagnosed with cancer. [106-108] Stroke has been reported to be associated with AD among elderly patients. The relation is strong in the presence of certain vascular risk factors. [109, 110] Recently, there is accumulating evidence demonstrating that hyperglycemia is a potential risk factor for the development of cognitive impairment or AD. [111, 112] It has been reported that AD patients have a high risk of developing certain types of epilepsy and subclinical epileptiform activity. [113]

|	genitourinary system agents	hormones	antiinfectives	anticancer	immuno-modulators	musculo-skeletal system agents	nervous system agents	respiratory system agents	cardiovascular system agents	blood system / hematological agents	digestive / metabolic agents
arthritis	11	8	5	6	5	9	4	9	6	4	4
atherosclerosis	0	3	0	1	2	6	2	0	1	3	2
cardiovascular disease	6	2	7	5	6	9	4	3	21	5	5
dementia	0	15	8	6	10	6	18	9	10	20	14
depression	6	8	6	4	5	3	6	12	2	4	5
diabetes	17	19	18	10	13	12	15	15	15	13	17
epilepsy	11	6	5	4	3	9	5	9	5	4	3
hypertension	17	2	5	4	7	3	6	6	6	9	5
inflammation	6	13	13	9	17	15	12	12	8	12	11
neoplasm	11	11	18	41	21	12	14	15	17	14	19
obesity	0	3	5	4	4	6	2	0	6	2	7
schizophrenia	11	3	6	2	5	3	5	6	1	4	3
stroke	6	6	3	3	3	6	6	6	4	6	5

Figure 10. (A) Co-occurrence of the AD concept with other diseases concepts in the CAS Content Collection documents, with the associated number of documents shown;

(B) Classes of drugs explored for repurposing to AD treatment, with associated number of documents indicated; Inset: Annual growth of the drug repurposing-related documents (journal articles and patents). (C) Correlation between diseases co-occurring with AD and potential drugs for repurposing to AD as judged by the concepts co-occurrence in the CAS Content Collection documents.

Pharmaceutical targets and genetic risk factors

There are multiple potential pharmaceutical targets for the treatment of AD, as currently documented in the Common Alzheimer's Disease Research Ontology (CADRO)[114], including amyloid beta (Aβ) peptide, tau protein, apolipoprotein E4 (APOE4), lipids, lipoprotein and neurotransmitter receptors, enzymes, and many other regulators, and multitarget interventions. [115] Amyloid beta and tau proteins are the major undisputed pharmacological targets for disease modifying therapies of AD (Figure 11A, lower panel). The fastest growing target according to the CAS data is the transactive response DNA binding protein of 43 kDa (TDP-43), a nuclear protein involved in the regulation of gene expression (Figure 11A, upper panel). Cytoplasmic inclusion bodies comprising phosphorylated and truncated forms of TDP-43 have been found in multiple AD cases, as well as in other proteinopathies including amyotrophic lateral sclerosis, frontotemporal dementia. TDP-43 deposits have been also found in neurons with neurofibrillary tangles. There is emerging evidence that TDP-43 may spread in a prion-like manner, which means it could propagate from cell to cell, potentially contributing to the progression of neurodegenerative diseases like AD. [116] The most common genetic risk factor for AD, apolipoprotein E4 (APOE4), is associated with increased frequency of TDP-43 pathology. [117-120]

Angiotensin-converting enzyme (ACE) is another pharmacological target of AD exhibiting rapid growth in the number of publications included in the CAS Content Collection (Figure 11A, upper panel). Indeed, among the Aβ degrading enzymes such as neprilysin, insulin-degrading enzyme, endothelin-converting enzyme, and ACE, the last one is the most commonly targeted enzyme by inhibitors, mainly because it plays central role in the regulation of blood pressure and hypertension. [121, 122] However, genetic, pathological and biochemical studies have associated ACE with AD. [123] ACE has been shown able to convert neurotoxic β-amyloid protein Aβ42 to Aβ40. Aβ42 is believed to play a causative role in the development of AD, whereas Aβ40 exhibits neuroprotective activities against Aβ42 aggregation as well as against metal-induced oxidative damage. [124]

15

Figure 11. Pharmacological targets (A) and genetic risk factors (B) of AD. Upper panels illustrate the relative growth of the number of documents in the last five years (2019-2023), while the lower panels show the number of documents related to various major target proteins and genetic risk factors.

Genetic factors play a major role in the development of AD. In the late-onset type of AD, which applies to 95% of cases, the underlying etiology is supposedly caused by a combination of genetic and environmental factors in the approximate ratio of 70:30, respectively. [125] In the rare cases of early onset AD, the disease etiology is allegedly almost exclusively genetic. [126-130] Hence, genetics seem to play a major role in all types of AD.

Mutations in the dominant genes including Amyloid Precursor Protein (APP), Presenilin-1 (PSEN-1), Presenilin-2 (PSEN-2), apolipoprotein E (ApoE), and others, are associated with AD. [28, 131] From thirty discovered mutations in the APP gene, twenty-five have been found related to AD and causing accumulation of Aβ. [132, 133] PSEN1 and PSEN2 genes are also the autosomal dominant form of early-onset AD. Mutation in PSEN1 gene is more frequent, with more than 200 mutations, while in the PSEN2 gene only a rare form with less than 40 mutations was identified. [27, 134] Apolipoprotein E (ApoE), especially ApoEε4 plays an important role in Aβ deposition as a senile plaque. It has been found to cause cerebral amyloid angiopathy, known as a marker for AD. [135] ApoEε4 is also related to vascular damage in the brain, leading to AD pathogenesis. [136]

16

Adenosine triphosphate (ATP)-binding cassette transporter A1 (ABCA1) is known to regulate the stability of ApoE lipidation. Mutation in the ABCA1 gene has been reported to result accumulation of cholesterol in tissues, and AD pathogenesis. [136]   In contrast to PSEN1, PSEN2, and APP mutations, Clusterin (CLU) and Bridging Integrator 1 (BIN1) genes are risk factors for late-onset AD. [137-139]

According to CAS Content Collection, the largest number of documents associate APP, ApoE, PSEN-1, and CLU genes with AD pathogenesis (Figure 11B, lower panel). ABCA1, CLU, BIN1, and ApoE are the risk factors exhibiting the fastest growth in the number of documents in the last five years (2019-2023) (Figure 11B, upper panel).

We further considered the correlation between the genetic risk factors of the AD and the pharmacological targets. Understanding this correlation can provide insights into the underlying mechanisms of the disease and guide drug development efforts. Indeed, many pharmacological approaches for treating AD target the pathological hallmarks of the disease:

   o Drugs targeting amyloid-beta include β-secretase inhibitors, γ-secretase inhibitors, and monoclonal antibodies that bind to amyloid-beta and promote its clearance.
   o Drugs targeting tau protein include tau aggregation inhibitors, tau kinase inhibitors, and immunotherapies aimed at reducing tau pathology.
   o Anti-inflammatory drugs target neuroinflammation, which is implicated in Alzheimer's disease progression.
   o Neuroprotective agents aim to preserve neuronal function and viability, potentially slowing disease progression.

The co-occurrences of the genetic risk factors and the pharmacological targets concepts in the documents of the CAS Content Collection related to AD are illustrated in Figure 12.   APP co-occurs in documents with all target proteins, but with highest frequency with BACE1 and PD-4; ApoE most frequently co-occurs with TDP-43 and ACE, and PSEN-1 – most frequently with GSK-3β and JNK.

Figure 12. Co-occurrences of the genetic risk factors and pharmacological target proteins concepts in documents in the CAS Content Collection related to AD.

Role of primary aging hallmarks in Alzheimer´s disease

Aging is characterized with a time-dependent gradual accumulation of cell damage and continual physiological functional decline. As such, it is also the most profound risk factor for many diseases. Neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's diseases, as well as sensorial disfunctions all increase considerably upon aging. [140-143] With the growth in aging population and increasing burden of health care for people with age-related diseases, including AD, intense efforts have been put forth to understand and prevent the effects of aging. The major cellular and molecular hallmarks of aging have been identified and their relationships to age-related diseases, and especially to AD as one of the most common neurodegenerative disorders, have been explored. [144]

The hallmarks of aging include a variety of interrelated molecular and cellular mechanisms that act jointly to manage the aging process. [145] Aging has been characterized as a progressive degeneration accompanied by processes like stem cell exhaustion, extracellular matrix modifications, cellular senescence, tissue inflammation, and metabolic dysfunction. [69, 72] These cellular and tissue modifications reflect inherent molecular deviations in mitochondria, epigenetics, DNA maintenance, proteostasis, intercellular interactions, and nutrient sensing, which cause genomic instability and impairment, including telomere dysfunction. [69, 72]

DNA damage markers have been found in brain regions of AD patients [26-30], indicating that DNA damage may be an important pathological cause of AD, particularly in late-onset AD cases. [146-148] Genomic instability impacts the expression of the genes linked to mitochondrial and metabolic dysfunction, altered proteostasis, and age-related inflammation (inflammaging), which are intrinsically involved in aging, and supports the view that DNA damage could be the root of aging and AD. [149, 150] Hence, targeting DNA damage or other aging hallmarks offers an approach to developing treatments to combat age-related diseases, including AD. [149]

Telomeres shorten with age, and some 50 nucleotides are lost upon each cell cycle. Neurons, as post-mitotic cells, are not expected to have their telomeres shortened, yet they may still accumulate DNA damage, causing cellular senescence or even apoptosis. [151, 152] Neural stem cells, in contrast, are proliferative and affected by aging, so telomere maintenance is vital for their viability and self-renewal potential, while telomere shortening may trigger cognitive impairment. [153] Epigenetic mechanisms are known to contribute directly to aging and aging-related diseases. [154] It has been shown that epigenetics play a key role in maintaining genome integrity and regulating gene expression, and its dysfunction is closely related to AD pathogenesis. [155]

DNA methylation refers to the attachment of a methyl group to the DNA chain and is considered one of the aging hallmarks. [69] Abnormal DNA methylation has been associated with many AD susceptibility genes, including amyloid precursor protein (APP), β- and γ-secretases, apolipoprotein E, to mention a few. [144, 156, 157] As an organism ages, the proteome, like the genome, is easily damaged, so loss of proteostasis come up another hallmark of aging. [69] At the early and advanced stages of AD, alteration of protein synthesis pathways, including nuclear chaperones, ribosomal proteins, and elongation factors, has been detected in the frontal cortex and hippocampus. [158, 159] Furthermore, proteins associated with various other biological processes are also aberrantly downregulated due to genomic instability in the AD brain. [160, 161]

A search in the CAS Content Collection by SciFinder-n [162] for co-occurrence of AD and the aging hallmarks term that AD is most often discussed in the context of mitochondrial dysfunction, impaired autophagy, and lipid metabolism disorders (Figure 13A). Indeed, **mitochondrial dysfunction** has been found related to virtually all the associated AD pathologies, including accumulation of plaques and tangles in the hippocampal and cortical neurons of the brain, abnormal microvasculature, interneuron miscommunication, enhanced β-amyloid production, elevated inflammatory response, advanced production of reactive oxygen species, impaired brain metabolism, tau hyperphosphorylation, and disruption of acetylcholine signaling. [163-171]

Autophagy is an evolutionarily conserved lysosome-dependent cellular pathway closely related to modulation of protein metabolism, by way of which damaged organelles and misfolded proteins are degraded and recycled to preserve protein homeostasis. Accumulating evidence has revealed that **impaired autophagy** critically contributes to AD pathogenesis. [172, 173] Immature autophagosome accumulation and dystrophic neurites have been detected in the AD patients brains. [173] Furthermore, the expression of certain autophagy-related proteins has been reported to be downregulated in AD brains. [174-176] Increasing evidence has recently indicated that dysfunctional autophagy is not just correlated with AD pathologies, but is possibly a causative factor for AD development. Various AD risk genes, including PSEN1, PICALM,

CLU, TREM2 have been shown to modulate autophagy. Therefore, promoting autophagy to augment the elimination of misfolded proteins is recommended to be an opportunity for AD therapy. [172]

Though the abnormal accumulation of lipids has been described in the very first report of AD neuropathology [177, 178], it has not been until recently that **lipid homeostasis impairment** has become a focus of AD research. [179] Lipidomic and metabolomic studies have consistently exhibited alterations in the levels of various lipid classes emerging in early stages of AD brains. Multidimensional interactions between lipid metabolism and key AD pathogenic pathways including amyloidogenesis, bioenergetic deficit, oxidative stress, neuroinflammation, and myelin degeneration have been revealed. [179]

With respect to the relative growth in the number of documents correlating AD with various aging hallmarks, telomere attrition exhibits the highest growth, followed by the dysregulated nutrient sensing (Figure 13B). Indeed, the research of telomere biology is one of the most invested areas of research in AD prevention and treatment, due to its involvement in many age-related diseases. [180, 181] The presence of shorter telomeres in multiple somatic samples from AD patients, especially in leukocytes, has been reported. [182] It has been suggested that the telomere shortening in peripheral leukocytes might be explained by certain known AD features on a molecular level such as high inflammatory cytokine levels and oxidative stress. [183-185]

Deregulated nutrient sensing is increasingly thought to play a role in the pathophysiology of neurodegenerative diseases such as AD. [186-188] Nutrient sensing is increasingly emerging both as a key modulator of neurogenesis, and, through mTOR, of the autophagic process. [189, 190] The extensive role that deregulated nutrient sensing may play in dementia offers a possible therapeutic pathway, as many nutrient sensing-modulating therapeutics already exist. [191]


Figure 13. Correlation between primary aging hallmarks and AD as reflected by their co-occurrence in the documents in the CAS Content Collection: (A) number of documents and (B) relative growth in the years 2019-2023 related to the respective aging hallmark.

Approved Drugs

Several prescription drugs have been approved by the US FDA for Alzheimer's disease to help either manage the symptoms of or to treat the disease progression (Table 1), plus some in late phases of clinical trials (Table 2). The majority of the FDA-approved drugs work best for people in the early stages of Alzheimer's disease. There are currently no known interventions that will cure Alzheimer's disease.

Cholinesterase inhibitors are prescribed to treat symptoms associated with memory, thinking, language, judgment and other thinking processes. These medications decrease the breakdown of acetylcholine, a chemical messenger important for memory and learning. These drugs support communication between nerve cells. [53, 57]

- Donepezil (Aricept®) – approved to treat all stages of AD
- Rivastigmine (Exelon®) – approved for mild-to-moderate AD
- Galantamine (Razadyne®) – approved for mild-to-moderate AD
- Alpha-1062 (galantamine prodrug) – FDA New Drug Application acceptance for mild-to-moderate AD

Glutamate regulators are prescribed to improve memory, attention, thinking, language and the ability to perform simple tasks. This type of drug works by regulating the activity of glutamate, a chemical messenger that helps the brain process information. [53, 57]
- Memantine (Namenda®) – approved for moderate-to-severe AD.

Cholinesterase inhibitor + glutamate regulator - this type of drug is a combination therapy. [53, 57]

- Donepezil + Memantine (Namzaric®) – approved for moderate-to-severe AD.

Orexin receptor antagonist - inhibits the activity of orexin, a type of neurotransmitter involved in the sleep-wake cycle. [53, 57]
- Suvorexant (Belsomra®) – approved for treatment of insomnia, effective for patients with mild to moderate AD.

Atypical antipsychotics drugs target the serotonin and dopamine chemical pathways in the brain. They are mainly used to treat schizophrenia and bipolar disorder and as add-on therapies for depressive disorders. These medications are also used to treat dementia-related behaviors. [53, 57]

- Brexpiprazole (Rexulti®) – approved for treatment of agitation associated with dementia due to AD.

Anti-amyloids are the recent hope and promise in AD treatment. [192, 193] They work by attaching to and removing a protein that accumulates into plaques, β-amyloid, from the brain. These monoclonal antibody drugs target β-amyloid at a different stage of plaque formation (Figure 14). However, the results of the ongoing clinical trials are still controversial, and for the time being the benefits of these drugs seem to be harder to quantify than potential harms. [194, 195]
- Aducanumab (Aduhelm) is an anti-amyloid antibody, which received accelerated FDA approval for treatment of early AD in 2021. [196] It has been the first medication to demonstrate that removing β-amyloid from the brain reduces cognitive and functional decline. Aducanumab is being discontinued by its manufacturer, Biogen. The company stated that this decision is not related to any safety or efficacy concerns. [197]
- Lecanemab (Leqembi) is an anti-amyloid antibody, which received traditional FDA approval for treatment of early AD. [198] It is the second therapy to demonstrate that removing β-amyloid from

the brain reduces cognitive and functional decline in patients living with early AD and the first to show clinical benefits. [199, 200]

• Donanemab is an anti-amyloid antibody, currently under FDA review for approval, as a possible treatment for AD. [201, 202] Application for full FDA approval initially took place in 2023 with the FDA delaying approval evaluation until later in 2024. [203] It targets β-amyloid plaque, potentially reducing the excess protein reducing cognitive and functional decline. [201]


Figure 14. Scheme of the formation of amyloid plaques and target sites of the anti-amyloid antibody drugs (Adapted from "Cleavage of Amyloid Precursor Protein", by BioRender.com (2024). Retrieved from https://app.biorender.com/biorender-templates).

Table 1. FDA approved medications that mitigate symptoms of Alzheimer's dementia or change the disease progression [53, 57, 204-206]

Drug (Generic/Brand)	CAS RN	Structure	Drug type	Treats	No. Docs in CAS Content Collection
Tacrine (Cognex®) (withdrawn from market)	321-64-2		Cholinesterase inhibitor, cholinergic agonist	Cognitive symptoms	4238
Brexpiprazole (Rexulti®)	913611-97-9		Atypical antipsychotic	Non-cognitive symptoms: agitation associated with dementia	662
Donepezil (Aricept®)	120014-06-4		Cholinesterase inhibitor	Cognitive symptoms (memory and thinking)	5015
Galantamine (Razadyne®)	357-70-0		Cholinesterase inhibitor	Cognitive symptoms (memory and thinking)	5313
Memantine (Namenda®)	19982-08-2		NMDA antagonist	Cognitive symptoms (memory and thinking)	5959
Memantine + Donepezil (Namzaric®)	914296-81-4	N/A	NMDA antagonist, Cholinesterase inhibitor	Cognitive symptoms (memory and thinking)	24
Rivastigmine (Exelon®)	123441-03-2		Cholinesterase inhibitor	Cognitive symptoms (memory and thinking)	3806
Suvorexant (Belsomra®)	1030377-33-3		Orexin receptor antagonist	Non-cognitive symptoms: Insomnia	468
Lecanemab (Leqembi®)	1260393-98-3	Protein/Peptide Sequence Sequence Length: 1346	Anti-amyloid antibody	Disease-modifying treatment – changes disease progression	196
Aducanumab (Aduhelm®)	1384260-65-4	Protein/Peptide Sequence Sequence Length: 1334	Anti-amyloid antibody	Disease-modifying treatment – changes disease progression	511

23

Donanemab (N₃pG)	1931944-80-7	Protein/Peptide Sequence Sequence Length: 1326	Anti-amyloid antibody	Disease-modifying treatment – changes disease progression (development code LY3002813). Phase 3 clinical trial (NCT04437511), application for full approval	59
Alpha-1062	1542321-58-3		Galantamine prodrug, Cholinesterase inhibitor	Cognitive symptoms (memory and thinking), application for New Drug Application approved	5

Drugs in Clinical Trials

Clinical trials researching the treatment of Alzheimer's disease are explored in this section to gain an overall view of the past and current state of clinical development. Over 2200 clinical trials have been registered on clinicaltrials.gov over the last 20 years for Alzheimer's diseases, reinforcing a strong interest in clinical development of treatments for this devastating disease. Figure 15. shows an increasing oscillating curve starting at around 40 clinical trials and raising to around 200 clinical trials per year, between the years 2003 to 2023.


Figure 15. Number of Alzheimer's disease therapeutic clinical trials by year.

Analysis of Alzheimer's disease therapeutic clinical trials reveals that around 41% of all trials are not phased (Figure 16A), including trials such as ones testing medical devices or behavioral interventions. The phase that contains the next largest group of trials is Phase I and Phase II studies, researching the safety and efficacy of newer anti-Alzheimer's disease agents. Over half of all clinical trials in the past 10 years have been completed (Figure 16B). The status with the next largest group of trials is the recruiting status which is encouraging as new clinical trials are created and carried out to research the treatment of Alzheimer's disease, offering hope to patients worldwide.

Exemplary ongoing Phase III and Phase II clinical trials and their studied drugs are highlighted in in Table 1. along with their CAS RN, structure, drug type, and number of publications in the CAS Content Collection.

25

A

Early Phase I	Phase I	Phase I/II	Phase II	Phase II/III	Phase III	Phase IV	NA
2%	17%	3%	20%	2%	9%	5%	41%

B

Not yet recruiting	Recruiting	Active	Completed	Withdrawn/Terminated/Suspended
5%	20%	5%	59%	12%

Figure 16. Percentage of Alzheimer's disease clinical trials in various: (A) phases; (B) statuses.

Table 2. Exemplary ongoing clinical trials Phase III and II of anti-Alzheimer therapy

Drug name	CAS RN	Structure	Drug type	NCT Number	No. Docs in the CAS Content Collection
Phase III					
Gantenerumab	1043556-46-2	Protein/Peptide Sequence Sequence Length: 1342	Anti-amyloid antibody	NCT01760005	221
CAD106 (Amilomotide)	1176290-10-0	N/A	Amyloid vaccine	NCT02565511	28
TRx0237 (LMTX, Methotrexate)	59-05-2		Tau protein aggregation inhibitor	NCT02245568	73973
AGB101 (Levetiracetam)	102767-28-2		Low-dose levetiracetam - improves synaptic function and reduces amyloid-induced neuronal hyperactivity	NCT05986721	6393

26

ALZT-OP 1 (cromolyn + ibuprofen)	2396743-42-1	N/A	Combination treatment (mast cell stabilizer + NSAID)	NCT02547818	3
ANAVEX2-73 (blarcamesine hydrochloride)	195615-84-0	• HCl	Sigma-1 receptor agonist, Muscarinic M2 and M3 receptor antagonist-restores cellular homeostasis by targeting sigma-1 and muscarinic receptors	NCT04314934	33
Azeliragon	603148-36-3		Small-molecule RAGE inhibitor	NCT02080364	54
BHV4157 (troriluzole)	1926203-09-9		Glutamate modulator	NCT03605667	30
Masitinib	790299-79-5		Tyrosine kinase inhibitor	NCT05564169	616
Remternetug	2571940-41-3	Protein/Peptide Sequence Sequence Length: 1330 (451, 451, 214, 214)	Anti-amyloid antibody	NCT05463731	1
Simufilam	1224591-33-6		Stabilizing a critical protein in the brain	NCT04994483	14
Solanezumab	955085-14-0	Protein/Peptide Sequence Sequence Length: 1322	Anti-amyloid antibody	NCT00905372 ; NCT00904683	318
Valiltramiprosate (ALZ-801)	1034190-08-3		β-Amyloid inhibitor, oral prodrug of the active agent tramiprosate	NCT04770220	19

Phase II

Varoglutamstat (PG912)	1276021-65-8		Glutaminyl cyclase inhibitor metalloenzyme	NCT03919162	14
Crenezumab	1095207-05-8	Protein/Peptide Sequence; Sequence Length: 1314	Anti-amyloid antibody	NCT03114657	186
ABBV 8E12	2096513-89-0	Protein/Peptide Sequence	Monoclonal antibody, prevents tau propagation;	NCT02880956	33
ABvac40	N/A	N/A	Active vaccine against the C-terminal end of Aβ40	NCT03113812	1
E-2814	2690265-18-8	Protein/Peptide Sequence Sequence Length: 1334 (448, 448, 219, 219)	IgG1 monoclonal anti-tau antibody	NCT04971733 / NCT01760005	10
Gosuranemab	1788032-39-2	Protein/Peptide Sequence Sequence Length: 1326	IgG4 monoclonal anti-tau antibody	NCT03352557	43
Zagotenemab	2019133-28-7	Protein/Peptide Sequence Sequence Length: 1322	IgG4 monoclonal anti-tau antibody	NCT03019536	17
Semorinemab	2159141-27-0	Protein/Peptide Sequence	IgG4 monoclonal anti-tau antibody	NCT03289143	30
Daratumumab	945721-28-8	Protein/Peptide Sequence Sequence Length: 1332	IgG1, monoclonal anti-CD38 antibody; regulates microglial activity	NCT02252172	2051
IONIS-MAPTRx	2857842-32-9	Oligonucleotide	MAPT targeting oligonucleotide as Tau protein expression inhibitor; tau antisense oligonucleotide - reduces tau production	NCT03186989	3
Lithium	7439-93-2	Li	Neurotransmitter receptors ion channel modulator	NCT03185208	228,972
Nilotinib	641571-10-0		Tyrosine kinase inhibitor	NCT01784068	5241

28

Posiphen	116839-68-0		Selective inhibitor of APP	NCT04524351	56
Riluzole	1744-22-5		Glutamate receptor antagonist	NCT01703117	2651
PTI 125	1224591-33-6		Filamin A protein inhibitor	NCT04079803	14
PQ912	1276021-65-8		Glutaminyl cyclase inhibitor	NCT02389413	14

Drug repurposing

Since there is no cure for AD, drug repurposing studies have been intensely searching to identify existing drugs that could be repositioned to treat AD. [207-212] As pharmaceutical development process is both time-consuming and costly, drug repurposing provides a chance to accelerate it by exploring the AD-related effects of agents approved for other disorders. These drugs have established safety profiles, pharmacokinetic description, formulations, dosages, and manufacturing procedures. Recently, *in silico* pharmacology has been widely applied and various computer applications including machine learning and artificial intelligence approaches have been explored in identifying potential drugs for repurposing to AD. [213-216] Drug repurposing has already been attempted in AD with various methodologies applied and several clinical trials are currently evaluating drug-repurposing candidates for AD. [207, 217-219] Fifty widely discussed drugs for AD repurposing [207-219] are summarized in Table 3.

Table 3. Exemplary drugs commonly considered for repurposing to AD, along with the number of documents in the CAS Content Collection related to them

Drug	CAS RN	No. Docs	Drug type
Lithium	7439-93-2	958	psychiatric
Metformin	657-24-9	741	antidiabetic
Risperidone	106266-06-2	704	antipsychotic
Nicotinamide	98-92-0	693	vitamin
Atorvastatin	134523-00-5	574	cardiovascular
Tamoxifen	10540-29-1	503	anti-cancer
Clozapine	5786-21-0	437	antipsychotic
Pioglitazone	111025-46-8	436	anti-diabetic
Tacrolimus	104987-11-3	416	immunologic
Aripiprazole	129722-12-9	332	antipsychotic
Dronabinol	1972-08-3	326	appetite stimulant, antiemetic
Riluzole	1744-22-5	306	neurologic
Verapamil	52-53-9	305	Ca-channel blocker, antihypertensive
Venlafaxine	93413-69-5	291	psychiatric
Escitalopram	128196-01-0	268	psychiatric
Bromocriptine	25614-03-3	260	dopamine agonist
Bupropion	34911-55-2	257	antidepressant
Liraglutide	204656-20-2	253	antidiabetic
Levetiracetam	102767-28-2	246	Neurologic, antiepileptic
Methylphenidate	113-45-1	231	psychiatric
Mirtazapine	85650-52-8	230	psychiatric
Raloxifene	84449-90-1	229	estrogen receptor modulator
Thalidomide	50-35-1	225	immunomodulator
Vorinostat	149647-78-9	215	anti-cancer
Losartan	114798-26-4	188	cardiovascular
Leuprolide	53714-56-0	188	hormonal

Sunitinib	557795-19-4	181	anti-cancer
Lenalidomide	191732-72-6	176	anti-cancer, hematologic
Nilotinib	641571-10-0	176	anti-cancer
Amlodipine	88150-42-9	173	cardiovascular
Brexanolone	516-54-1	169	psychiatric
Zidovudine	30516-87-1	159	HIV antiviral
Telmisartan	144701-48-4	150	cardiovascular
Zolpidem	82626-48-0	148	neurologic
Prazosin	19216-56-9	133	cardiovascular
Cilostazol	73963-72-1	113	hematologic
Candesartan	139481-59-7	108	cardiovascular
Allopurinol	315-30-0	105	uric acid reducer
Deferiprone	30652-11-0	100	hematologic
Salsalate	552-94-3	98	anti-inflammatory
Montelukast	158966-92-8	95	anti-inflammatory
Vandetanib	443913-73-3	92	anti-cancer
Efavirenz	154598-52-4	92	HIV antiviral
Perindopril	82834-16-0	87	cardiovascular
Zopiclone	43200-80-2	78	neurologic
Valacyclovir	124832-26-4	76	antiviral
Dabigatran Sodium	211914-51-1	69	hematologic
phenylbutyrate	1716-12-7	61	anti-cancer, cystic fibrosis
Dapagliflozin	461432-26-8	60	antidiabetic

We identified over 700 documents in CAS Content Collection discussing drug repurposing for AD. The number of AD drug repurposing publications increased dramatically over the last decade – from 13 documents in 2013 to 147 in 2023 (Figure 10B, Inset). The distribution of the considered potential repurposed drug classes with respect to their original disease targets according to the CAS Content Collection is illustrated in Figure 10B. Predictably, drugs for repurposing to AD are most often searched within the pool of nervous system agents. Anticancer drugs, metabolic agents, and immunomodulators are also between the hopeful drugs for repurposing to AD (Figure 10B).

We further examined the correlation between diseases that co-occur with AD and the exploration of drug repurposing. Since AD is a complex neurodegenerative disorder, individuals with AD often have other health conditions or comorbidities. Some of these comorbidities may share underlying biological pathways or mechanisms with AD. By examining diseases that commonly co-occur with Alzheimer's, researchers may identify potential candidate drugs for repurposing. Overall, understanding the relationship between comorbidities of AD and the potential for drug repurposing can provide valuable insights into the development of new treatments or therapeutic strategies for this devastating condition. Exploration of drug repurposing for AD involves leveraging the shared pathophysiological mechanisms and existing drug libraries of comorbid conditions, employing a combination of biological and computational

approaches, and conducting rigorous clinical trials to validate the efficacy and safety of repurposed drugs.

The correlation between the concepts related to diseases co-occurring with AD and the exploring classes of drugs for repurposing to AD is illustrated in Figure 10C.   In addition to certain obvious correlations such as cancers (neoplasm) – anticancer agents and cardiovascular diseases – cardiovascular system agents, there are some worth mentioning:

Dementia – hematological agents: Studies have implicated vascular disorders as risk factors for dementia. Biological and epidemiological evidence have been reported concerning the role of certain hematologic factors such as homocysteine, cholesterol, fatty acids, antioxidants, and C-reactive protein in dementia. [220] Abnormal (low or high) levels of hemoglobin have been associated with an enhanced risk of dementia, including AD, which may be associated with differences in white matter integrity. [221] Association has been reported between blood leukocyte counts and increased risk of AD. [222]

Diabetes – hormones: An imbalance in sex hormones has been identified as having a critical impact on type 2 diabetes. Androgens have a noteworthy sex-dimorphic association with type 2 diabetes, since hyperandrogenism in females and hypogonadism in males are risk factors for type 2 diabetes. Thus, treatments aimed at correcting these sex hormone imbalance may prevent the development of type 2 diabetes or help in its treatment. [223]

Inflammation – immunomodulators: Inflammation is a central part of autoimmune diseases, which are caused by dysregulation of the immune system, involving imbalance between pro-inflammatory vs. anti-inflammatory mediators. [224]

Neoplasm – immunomodulators: Immunotherapy is treatment that uses your body's own immune system to help fight cancer. Many immunotherapeutic agents operate by activating an efficient antitumor response or reversing tumor-mediated immunosuppression through modulation of significant regulatory pathways. [225]

Future directions of research

Research on Alzheimer's disease is a dynamic field, with ongoing efforts aimed at understanding the underlying causes of the disease, developing effective treatments, and ultimately finding a cure. Understanding the molecular and cellular mechanisms underlying AD, including the role of β-amyloid plaques, tau protein tangles, neuroinflammation, and synaptic dysfunction, is a major focus of research. Advances in techniques such as imaging, genetics, and molecular biology are providing insights into the early stages of AD and potential targets for intervention.

Identifying reliable biomarkers for AD, including blood-based markers, cerebrospinal fluid markers, and imaging biomarkers, is crucial for early detection, accurate diagnosis, and monitoring disease progression. Recently, the first Alzheimer's treatments targeting disease pathophysiology became available to patients and accelerated this need. Research is ongoing to develop new and more sensitive biomarkers that can detect AD pathology in its earliest stages, even before symptoms appear, when treatments are most effective. [46, 226] Non-invasive diagnostic tests are showing great promise in detecting β-amyloid and tau protein biomarkers equivalent or superior to FDA-approved

CSF tests in the detection of AD pathology. [44] These diagnostic assays, more easily accessible, will help alleviate the bottleneck and unmet needs of healthcare professionals and patients in evaluating them for AD.

Drug development efforts are focused on targeting various aspects of AD pathology, including reducing β-amyloid production or aggregation, inhibiting tau protein accumulation, modulating neuroinflammation, and promoting synaptic function and neuronal survival. Immunotherapy approaches, such as monoclonal antibodies targeting β-amyloid or tau proteins, are being investigated in clinical trials as potential disease-modifying treatments. Combination therapies targeting multiple pathways involved in AD pathogenesis are also being explored.

Advances in genetics and personalized medicine are leading to a better understanding of individual differences in AD risk, progression, and response to treatment. Precision medicine approaches aim to tailor treatments and interventions to the specific genetic and biological characteristics of each individual, potentially improving treatment efficacy and minimizing side effects.

Research continues to explore the efficacy of non-pharmacological interventions, such as cognitive training, physical exercise, diet, and lifestyle modifications, in reducing the risk of AD and improving cognitive function and overall brain health. Multimodal interventions combining various lifestyle factors, such as diet, exercise, cognitive stimulation, and social engagement, are being studied for their potential synergistic effects on brain health.

The analysis of large-scale datasets, including genetic data, clinical data, imaging data, and digital biomarkers, using advanced computational techniques such as machine learning and artificial intelligence, holds promise for uncovering new insights into AD and predicting disease progression. Collaborative initiatives such as the AD Neuroimaging Initiative (ADNI) [227] and the Global Alzheimer's Association Interactive Network (GAAIN) [228] facilitate data sharing and collaboration among researchers worldwide.

While significant challenges remain in the fight against AD, sustained efforts in research, advocacy, and care have the potential to improve outcomes for individuals affected by the disease and advance our collective efforts toward a future without Alzheimer's.

Notes

The authors declare no competing financial interest.

Acknowledgement

Author Contribution

R.T. and J.M.S: Conceptualization, investigation, methodology, data acquisition, writing, editing. Q.A.Z.: Conceptualization, investigation, methodology, validation, data and resource acquisition. All authors have approved the submitted final version.

References

1.   Veljkovic, E., Xia, W., Phillips, B., Wong, E. T., Ho, J., Oviedo, A., Hoeng, J., and Peitsch, M., Chapter 2 - Alzheimer's Disease. In *Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases*, Veljkovic, E.; Xia, W.; Phillips, B.; Wong, E. T.; Ho, J.; Oviedo, A.; Hoeng, J.; Peitsch, M., Eds. Academic Press: 2018; pp 13-23.

2.   Savonenko, A. V., Melnikova, T., Li, T., Price, D. L., and Wong, P. C., Chapter 21 - Alzheimer Disease. In *Neurobiology of Brain Disorders*, Zigmond, M. J.; Rowland, L. P.; Coyle, J. T., Eds. Academic Press: San Diego, 2015; pp 321-338.

3.   Budson, A. E., and Solomon, P. R., Chapter 3 - Alzheimer's disease: (See Chapter 2 for additional information). In *Memory Loss*, Budson, A. E.; Solomon, P. R., Eds. W.B. Saunders: Edinburgh, 2011; pp 43-70.

4.   Boughey, J. G. F., and Graff-Radford, N. R., CHAPTER 65 - ALZHEIMER'S DISEASE. In *Neurology and Clinical Neuroscience*, Schapira, A. H. V.; Byrne, E.; DiMauro, S.; Frackowiak, R. S. J.; Johnson, R. T.; Mizuno, Y.; Samuels, M. A.; Silberstein, S. D.; Wszolek, Z. K., Eds. Mosby: Philadelphia, 2007; pp 846-858.

5.   Murray, M. J., and Murray, C. F., Chapter 118 - Alzheimer's Disease. In *Complications in Anesthesia (Second Edition)*, Atlee, J. L., Ed. W.B. Saunders: Philadelphia, 2007; pp 493-495.

6.   Doody, R. S., Alzheimer's Disease. In *Current Therapy in Neurologic Disease (Seventh Edition)*, Johnson, R. T.; Griffin, J. W.; McArthur, J. C., Eds. Mosby: Philadelphia, 2006; pp 311-314.

7.   What Happens to the Brain in Alzheimer's Disease? https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/what-happens-brain-alzheimers-disease#:~:text=Emerging%20evidence%20suggests%20that%20Alzheimer's,clumps%20into%20plaques%20between%20neurons. (accessed Feb 27, 2024).

8.   Armstrong, R. A. (2019) Risk factors for Alzheimer's disease. Folia Neuropathol 57, 87-105.

9.   Medical Tests for Diagnosing Alzheimer's. https://www.alz.org/alzheimers-dementia/diagnosis/medical_tests#:~:text=There%20is%20no%20single%20test,with%20Alzheimer's%20or%20another%20dementia. (accessed Feb 27, 2024).

10.   Ciccone, I. A Caregiver's Perspective on Embracing Love for Patients With Alzheimer Disease. https://www.neurologylive.com/view/caregiver-perspective-embracing-love-patients-ad (accessed Feb 28, 2024).

11.   Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia (accessed Feb 27, 2024).

12.	What Causes Alzheimer's Disease? https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/what-causes-alzheimers-disease#:~:text=to%20live%20independently.-,Aging%20and%20Alzheimer's%20risk,older%20may%20have%20Alzheimer's%20disease. (accessed Feb 27, 2024).

13.	Alzheimer's disease. https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447#:~:text=Scientists%20believe%20that%20for%20most,person%20will%20develop%20the%20disease. (accessed Feb 28, 2024).

14.	Hardy, J., and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (New York, N.Y.) 297, 353-356.

15.	Hardy, J. A., and Higgins, G. A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science (New York, N.Y.) 256, 184-185.

16.	Patterson, C., Feightner, J. W., Garcia, A., Hsiung, G.-Y. R., MacKnight, C., and Sadovnick, A. D. (2008) Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Canadian Medical Association Journal 178, 548-556.

17.	Iqbal, K., Liu, F., Gong, C. X., and Grundke-Iqbal, I. (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7, 656-664.

18.	Braak, H., and Del Tredici, K., Neurofibrillary Tangles. In *Encyclopedia of Movement Disorders*, Kompoliti, K.; Metman, L. V., Eds. Academic Press: Oxford, 2010; pp 265-269.

19.	Youssef, S. A., Chapter 66 - Pathology of Brain Aging and Animal Models of Neurodegenerative Diseases. In *Conn's Handbook of Models for Human Aging (Second Edition)*, Ram, J. L.; Conn, P. M., Eds. Academic Press: 2018; pp 899-908.

20.	Rajmohan, R., and Reddy, P. H. (2017) Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons. J Alzheimers Dis 57, 975-999.

21.	Chi, H., Chang, H. Y., and Sang, T. K. (2018) Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases. International journal of molecular sciences 19.

22.	Cai, Y., Liu, J., Wang, B., Sun, M., and Yang, H. (2022) Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets. Front Immunol 13, 856376.

23.	Kwon, H. S., and Koh, S.-H. (2020) Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Translational Neurodegeneration 9, 42.

24.	Badimon, A., Torrente, D., and Norris, E. H. (2023) Vascular Dysfunction in Alzheimer's Disease: Alterations in the Plasma Contact and Fibrinolytic Systems. International journal of molecular sciences 24.

25.	Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., and Kwakowsky, A. (2019) Vascular Dysfunction in Alzheimer's Disease: A Prelude to the Pathological Process or a Consequence of It? Journal of clinical medicine 8.

26.	Tang, Y. P., and Gershon, E. S. (2003) Genetic studies in Alzheimer's disease. Dialogues Clin Neurosci 5, 17-26.

27.	Lanoiselée, H. M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A. C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., et al. (2017) APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med 14, e1002270.

28.	Khanahmadi, M., Farhud, D. D., and Malmir, M. (2015) Genetic of Alzheimer's Disease: A Narrative Review Article. Iran J Public Health 44, 892-901.

29.	Familial Alzheimer's Disease. https://memory.ucsf.edu/genetics/familial-alzheimer-disease (accessed Feb 28, 2024).

30.	Alzheimer's Disease Genetics Fact Sheet. https://www.nia.nih.gov/health/genetics-and-family-history/alzheimers-disease-genetics-fact-sheet (accessed Feb 28, 2024).

31.   Rare types of dementia caused by genetic changes. https://www.alzheimers.org.uk/about-dementia/rare-dementia-types-caused-by-genetic-changes (accessed Feb 28, 2024).

32.   Rabinovici, G. D. (2019) Late-onset Alzheimer Disease. Continuum (Minneap Minn) 25, 14-33.

33.   Mattson, M. P. (2015) Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle. npj Aging and Mechanisms of Disease 1, 15003.

34.   Efthymiou, A. G., and Goate, A. M. (2017) Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk. Molecular Neurodegeneration 12, 43.

35.   Reitz, C., Rogaeva, E., and Beecham, G. W. (2020) Late-onset vs nonmendelian early-onset Alzheimer disease. Neurology Genetics 6, e512.

36.   Duyckaerts, C., Delatour, B., and Potier, M.-C. (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathologica 118, 5-36.

37.   Holtzman, D. M., Morris, J. C., and Goate, A. M. (2011) Alzheimer's disease: the challenge of the second century. Sci Transl Med 3, 77sr71.

38.   Takeda, S. (2019) Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors. Neurosci Res 141, 36-42.

39.   Stages of Alzheimer's. https://www.alz.org/alzheimers-dementia/stages (accessed Feb 28, 2024).

40.   Alzheimer's stages: How the disease progresses. https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-stages/art-20048448 (accessed Feb 28, 2024).

41.   Ciesielska, N., Sokołowski, R., Mazur, E., Podhorecka, M., Polak-Szabela, A., and Kędziora-Kornatowska, K. (2016) Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr Pol 50, 1039-1052.

42.   Jia, X., Wang, Z., Huang, F., Su, C., Du, W., Jiang, H., Wang, H., Wang, J., Wang, F., Su, W., et al. (2021) A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study. BMC Psychiatry 21, 485.

43.   Fasnacht, J. S., Wueest, A. S., Berres, M., Thomann, A. E., Krumm, S., Gutbrod, K., Steiner, L. A., Goettel, N., and Monsch, A. U. (2023) Conversion between the Montreal Cognitive Assessment and the Mini-Mental Status Examination. Journal of the American Geriatrics Society 71, 869-879.

44.   Barthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. Nature Medicine 30, 1085-1095.

45.   Henderson, J. C₂N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, A Robust Assay with High Concordance to Amyloid PET and CSF. https://c2n.com/news-releases/cnnbspdiagnostics-releases-the-precivityad2-blood-test-for-clinical-care (accessed May 29, 2024).

46.   Shea, D., Colasurdo, E., Smith, A., Paschall, C., Jayadev, S., Keene, C. D., Galasko, D., Ko, A., Li, G., Peskind, E., et al. (2022) SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers. Proc Natl Acad Sci U S A 119, e2213157119.

47.   Bodily, T. A., Ramanathan, A., Wei, S., Karkisaval, A., Bhatt, N., Jerez, C., Haque, M. A., Ramil, A., Heda, P., Wang, Y., et al. (2023) In pursuit of degenerative brain disease diagnosis: Dementia biomarkers detected by DNA aptamer-attached portable graphene biosensor. Proceedings of the National Academy of Sciences 120, e2311565120.

48.   Cummings, J. L., Dubois, B., Molinuevo, J. L., and Scheltens, P. (2013) International Work Group criteria for the diagnosis of Alzheimer disease. Med Clin North Am 97, 363-368.

49.   National Institute on Aging and Alzheimer's Association Lead Effort to Update Diagnostic Criteria for Alzheimer's Disease.

https://www.alz.org/blog/alz/july_2010/national_institute_on_aging_and_alzheimer_s_associ (accessed Feb 29, 2024).

50.   Alzheimer's and dementia. https://www.nia.nih.gov/health/alzheimers-and-dementia (accessed Feb 29, 2024).

51.   Yiannopoulou, K. G., and Papageorgiou, S. G. (2020) Current and Future Treatments in Alzheimer Disease: An Update. J Cent Nerv Syst Dis 12, 1179573520907397.

52.   Saljoughian, M. (2023) Alzheimer's Disease and Current Treatment. U.S. Pharmacist 48, 22-24.

53.   How Is Alzheimer's Disease Treated? https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated (accessed Feb 28, 2024).

54.   Treatments for Alzheimer's. https://www.alz.org/alzheimers-dementia/treatments (accessed Apr 12, 2024).

55.   Alzheimer's Disease Treatments. https://www.nm.org/conditions-and-care-areas/neurosciences/alzheimers-disease/treatments#:~:text=Donepezil%20(Aricept)%2C%20Rivastigmine%20(,for%20the%20formation%20of%20memories. (accessed Apr 12, 2024).

56.   Grossberg, G. T. (2003) Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on. Curr Ther Res Clin Exp 64, 216-235.

57.   Medications for Memory, Cognition and Dementia-Related Behaviors. https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory (accessed Feb 28, 2024).

58.   What Are Stimulating Activities for People with Alzheimer's? https://www.healthline.com/health/alzheimers/activities-for-alzheimers (accessed Apr 12, 2024).

59.   Gottlieb, S., *Mental activity may help prevent dementia*. BMJ. 2003 Jun 28;326(7404):1418.: 2003.

60.   Schultz, S. A., Larson, J., Oh, J., Koscik, R., Dowling, M. N., Gallagher, C. L., Carlsson, C. M., Rowley, H. A., Bendlin, B. B., Asthana, S., et al. (2015) Participation in cognitively-stimulating activities is associated with brain structure and cognitive function in preclinical Alzheimer's disease. Brain Imaging Behav 9, 729-736.

61.   Forstmeier, S., Maercker, A., Savaskan, E., and Roth, T. (2015) Cognitive behavioural treatment for mild Alzheimer's patients and their caregivers (CBTAC): study protocol for a randomized controlled trial. Trials 16, 526.

62.   Reid, L. D., Avens, F. E., and Walf, A. A. (2017) Cognitive behavioral therapy (CBT) for preventing Alzheimer's disease. Behav Brain Res 334, 163-177.

63.   González-Martín, A. M., Aibar Almazán, A., Rivas Campo, Y., Rodríguez Sobrino, N., and Castellote Caballero, Y. (2023) Addressing depression in older adults with Alzheimer's through cognitive behavioral therapy: systematic review and meta-analysis. Frontiers in Aging Neuroscience 15.

64.   Patel, B., Perera, M., Pendleton, J., Richman, A., and Majumdar, B. (2014) Psychosocial interventions for dementia: from evidence to practice. Advances in Psychiatric Treatment 20, 340-349.

65.   Howe, E. (2008) Key psychosocial interventions for Alzheimer's disease: an update. Psychiatry (Edgmont) 5, 23-27.

66.   CAS Content Collection. https://www.cas.org/about/cas-content (accessed Mar 31, 2024).

67.   Guerreiro, R., and Bras, J. (2015) The age factor in Alzheimer's disease. Genome Med 7, 106.

68.   Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., and Bohr, V. A. (2019) Ageing as a risk factor for neurodegenerative disease. Nature Reviews Neurology 15, 565-581.

69.   López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., and Kroemer, G. (2013) The hallmarks of aging. Cell 153, 1194-1217.

70.   López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., and Kroemer, G. (2023) Hallmarks of aging: An expanding universe. Cell 186, 243-278.

71.   Mattson, M. P., and Arumugam, T. V. (2018) Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States. Cell Metab 27, 1176-1199.

72.   Tenchov, R., Sasso, J. M., Wang, X., and Zhou, Q. A. (2024) Aging Hallmarks and Progression and Age-Related Diseases: A Landscape View of Research Advancement. ACS Chemical Neuroscience 15, 1-30.

73.   Hillen, H. (2019) The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer's Disease. Front Neurosci 13, 1154.

74.   Glenner, G. G., and Wong, C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890.

75.   Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82, 4245-4249.

76.   De Gramont, A., Watson, S., Ellis, L. M., Rodón, J., Tabernero, J., De Gramont, A., and Hamilton, S. R. (2015) Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nature reviews Clinical oncology 12, 197-212.

77.   Godfrey, A., Vandendriessche, B., Bakker, J. P., Fitzer-Attas, C., Gujar, N., Hobbs, M., Liu, Q., Northcott, C. A., Parks, V., and Wood, W. A. (2021) Fit-for-purpose biometric monitoring technologies: leveraging the laboratory biomarker experience. Clinical and translational science 14, 62-74.

78.   Shanthi, K. B., Krishnan, S., and Rani, P. (2015) A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer's disease. SAGE Open Med 3, 2050312115598250.

79.   Teunissen, C. E., Chiu, M. J., Yang, C. C., Yang, S. Y., Scheltens, P., Zetterberg, H., and Blennow, K. (2018) Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease. J Alzheimers Dis 62, 1857-1863.

80.   Lee, J. C., Kim, S. J., Hong, S., and Kim, Y. (2019) Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers. Experimental & Molecular Medicine 51, 1-10.

81.   Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., and Pirttilä, T. (2009) Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain. Archives of Neurology 66, 382-389.

82.   Visser, P. J., Reus, L. M., Gobom, J., Jansen, I., Dicks, E., van der Lee, S. J., Tsolaki, M., Verhey, F. R. J., Popp, J., Martinez-Lage, P., et al. (2022) Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Molecular Neurodegeneration 17, 27.

83.   Medeiros, R., Baglietto-Vargas, D., and LaFerla, F. M. (2011) The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther 17, 514-524.

84.   Blennow, K., Hampel, H., Weiner, M., and Zetterberg, H. (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.

85.   Aschenbrenner, A. J., Li, Y., Henson, R. L., Volluz, K., Hassenstab, J., Verghese, P., West, T., Meyer, M. R., Kirmess, K. M., Fagan, A. M., et al. (2022) Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann Clin Transl Neurol 9, 1739-1751.

86.   Honig, L. S., Kang, M. S., Lee, A. J., Reyes-Dumeyer, D., Piriz, A., Soriano, B., Franco, Y., Coronado, Z. D., Recio, P., Mejía, D. R., et al. (2023) Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity. JAMA Network Open 6, e238214-e238214.

87.   Ashton, N. J., Puig-Pijoan, A., Milà-Alomà, M., Fernández-Lebrero, A., García-Escobar, G., González-Ortiz, F., Kac, P. R., Brum, W. S., Benedet, A. L., Lantero-Rodriguez, J., et al. (2023) Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimer's & Dementia 19, 1913-1924.

88.   Mandal, P. K., Maroon, J. C., Garg, A., Arora, N. K., Bansal, R., Kaushik, A., Samkaria, A., Kumaran, G., and Arora, Y. (2023) Blood Biomarkers in Alzheimer's Disease. ACS Chemical Neuroscience 14, 3975-3978.

89.   Hansson, O., Blennow, K., Zetterberg, H., and Dage, J. (2023) Blood biomarkers for Alzheimer's disease in clinical practice and trials. Nature Aging 3, 506-519.

90.   Angioni, D., Delrieu, J., Hansson, O., Fillit, H., Aisen, P., Cummings, J., Sims, J. R., Braunstein, J. B., Sabbagh, M., Bittner, T., et al. (2022) Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force. J Prev Alzheimers Dis 9, 569-579.

91.   Giau, V. V., Bagyinszky, E., Yang, Y. S., Youn, Y. C., An, S. S. A., and Kim, S. Y. (2019) Genetic analyses of early-onset Alzheimer's disease using next generation sequencing. Scientific reports 9, 8368.

92.   Troutwine, B. R., Hamid, L., Lysaker, C. R., Strope, T. A., and Wilkins, H. M. (2022) Apolipoprotein E and Alzheimer's disease. Acta Pharmaceutica Sinica B 12, 496-510.

93.   Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., and Liu, C.-C. (2022) ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Molecular Neurodegeneration 17, 72.

94.   Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging 49, 3508-3528.

95.   Maschio, C., and Ni, R. (2022) Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies. Front Aging Neurosci 14, 838034.

96.   Bao, W., Xie, F., Zuo, C., Guan, Y., and Huang, Y. H. (2021) PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. Frontiers in Aging Neuroscience 13.

97.   Chandra, A., Dervenoulas, G., and Politis, M. (2019) Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment. J Neurol 266, 1293-1302.

98.   Lombardi, G., Crescioli, G., Cavedo, E., Lucenteforte, E., Casazza, G., Bellatorre, A. G., Lista, C., Costantino, G., Frisoni, G., Virgili, G., et al. (2020) Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. Cochrane Database Syst Rev 3, Cd009628.

99.   Vemuri, P., and Jack, C. R. (2010) Role of structural MRI in Alzheimer's disease. Alzheimer's Research & Therapy 2, 23.

100.   Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., and Hansson, O. (2018) CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology 91, e867-e877.

101.   Angiulli, F., Conti, E., Zoia, C. P., Da Re, F., Appollonio, I., Ferrarese, C., and Tremolizzo, L. (2021) Blood-Based Biomarkers of Neuroinflammation in Alzheimer's Disease: A Central Role for Periphery? Diagnostics (Basel) 11.

102.   Rauf, A., Badoni, H., Abu-Izneid, T., Olatunde, A., Rahman, M. M., Painuli, S., Semwal, P., Wilairatana, P., and Mubarak, M. S. (2022) Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases. Molecules 27.

103.   Jung, Y., and Damoiseaux, J. S. (2023) The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease. Brain 147, 12-25.

104.   Giacomucci, G., Mazzeo, S., Bagnoli, S., Ingannato, A., Leccese, D., Berti, V., Padiglioni, S., Galdo, G., Ferrari, C., Sorbi, S., et al. (2022) Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment. J Neurol 269, 4270-4280.

105.   Santiago, J. A., and Potashkin, J. A. (2021) The Impact of Disease Comorbidities in Alzheimer's Disease. Front Aging Neurosci 13, 631770.

106.   Driver, J. A., Beiser, A., Au, R., Kreger, B. E., Splansky, G. L., Kurth, T., Kiel, D. P., Lu, K. P., Seshadri, S., and Wolf, P. A. (2012) Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ 344, e1442.

107.   Roe, C. M., Fitzpatrick, A., Xiong, C., Sieh, W., Kuller, L., Miller, J., Williams, M., Kopan, R., Behrens, M. I., and Morris, J. (2010) Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74, 106-112.

108.   Zabłocka, A., Kazana, W., Sochocka, M., Stańczykiewicz, B., Janusz, M., Leszek, J., and Orzechowska, B. (2021) Inverse Correlation Between Alzheimer's Disease and Cancer: Short Overview. Mol Neurobiol 58, 6335-6349.

109.   Honig, L. S., Tang, M.-X., Albert, S., Costa, R., Luchsinger, J., Manly, J., Stern, Y., and Mayeux, R. (2003) Stroke and the Risk of Alzheimer Disease. Archives of Neurology 60, 1707-1712.

110.   Pinho, J., Quintas-Neves, M., Dogan, I., Reetz, K., Reich, A., and Costa, A. S. (2021) Incident stroke in patients with Alzheimer's disease: systematic review and meta-analysis. Scientific reports 11, 16385.

111.   Rojas-Carranza, C. A., Bustos-Cruz, R. H., Pino-Pinzon, C. J., Ariza-Marquez, Y. V., Gomez-Bello, R. M., and Canadas-Garre, M. (2018) Diabetes-Related Neurological Implications and Pharmacogenomics. Curr Pharm Des 24, 1695-1710.

112.   Lee, H. J., Seo, H. I., Cha, H. Y., Yang, Y. J., Kwon, S. H., and Yang, S. J. (2018) Diabetes and Alzheimer's Disease: Mechanisms and Nutritional Aspects. Clin Nutr Res 7, 229-240.

113.   Zawar, I., and Kapur, J. (2023) Does Alzheimer's disease with mesial temporal lobe epilepsy represent a distinct disease subtype? Alzheimer's & Dementia 19, 2697-2706.

114.   CADRO: Common Alzheimer's Disease Research Ontology. https://www.nia.nih.gov/news/cadro-common-alzheimers-disease-research-ontology (accessed Mar 13, 2024).

115.   Liggins, C., Snyder, H. M., Silverberg, N., Petanceska, S., Refolo, L. M., Ryan, L., and Carrillo, M. C. (2014) International Alzheimer's Disease Research Portfolio (IADRP) aims to capture global Alzheimer's disease research funding. Alzheimers Dement 10, 405-408.

116.   Smethurst, P., Newcombe, J., Troakes, C., Simone, R., Chen, Y. R., Patani, R., and Sidle, K. (2016) In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol Dis 96, 236-247.

117.   Meneses, A., Koga, S., O'Leary, J., Dickson, D. W., Bu, G., and Zhao, N. (2021) TDP-43 Pathology in Alzheimer's Disease. Molecular Neurodegeneration 16, 84.

118.   Hayes, L. R., and Kalab, P. (2022) Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD. Neurotherapeutics 19, 1061-1084.

119.   Babazadeh, A., Rayner, S. L., Lee, A., and Chung, R. S. (2023) TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia. Ageing Research Reviews 92, 102085.

120.   Youmans, K. L., and Wolozin, B. (2012) TDP-43: A new player on the AD field? Experimental Neurology 237, 90-95.

121.   Angiotensin-converting enzyme (ACE) inhibitors. https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/ace-inhibitors/art-20047480#:~:text=Angiotensin%2Dconverting%20enzyme%20(ACE)%20inhibitors%20are%20medicines%20that%20help,the%20heart%20to%20work%20harder. (accessed Apr 12, 2024).

122.   High Blood Pressure and ACE Inhibitors. https://www.webmd.com/hypertension-high-blood-pressure/treatment-ace-inhibitors (accessed Apr 12, 2024).

123.   Zou, K., and Michikawa, M. (2008) Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation? Rev Neurosci 19, 203-212.

124.   Liu, S., Ando, F., Fujita, Y., Liu, J., Maeda, T., Shen, X., Kikuchi, K., Matsumoto, A., Yokomori, M., Tanabe-Fujimura, C., et al. (2019) A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice. Journal of Biological Chemistry 294, 9760-9770.

125.   Dorszewska, J., Prendecki, M., Oczkowska, A., Dezor, M., and Kozubski, W. (2016) Molecular basis of familial and sporadic Alzheimer's disease. Current Alzheimer Research 13, 952-963.

126.   Jarmolowicz, A. I., Chen, H.-Y., and Panegyres, P. K. (2015) The patterns of inheritance in early-onset dementia: Alzheimer's disease and frontotemporal dementia. American Journal of Alzheimer's Disease & Other Dementias® 30, 299-306.

127.   Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., and Charbonnier, F. (1999) Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. The American Journal of Human Genetics 65, 664-670.

128.   van Duijn, C. M., de Knijff, P., Cruts, M., Wehnert, A., Havekes, L. M., Hofman, A., and Broeckhoven, C. V. (1994) Apolipoprotein E4 allele in a population–based study of early–onset Alzheimer's disease. Nature genetics 7, 74-78.

129.   Wingo, T. S., Lah, J. J., Levey, A. I., and Cutler, D. J. (2012) Autosomal recessive causes likely in early-onset Alzheimer disease. Archives of neurology 69, 59-64.

130.   Breijyeh, Z., and Karaman, R. (2020) Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules 25.

131.   Van Cauwenberghe, C., Van Broeckhoven, C., and Sleegers, K. (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 18, 421-430.

132.   Li, N. M., Liu, K. F., Qiu, Y. J., Zhang, H. H., Nakanishi, H., and Qing, H. (2019) Mutations of beta-amyloid precursor protein alter the consequence of Alzheimer's disease pathogenesis. Neural Regen Res 14, 658-665.

133.   Tcw, J., and Goate, A. M. (2017) Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease. Cold Spring Harb Perspect Med 7.

134.   Cai, Y., An, S. S., and Kim, S. (2015) Mutations in presenilin 2 and its implications in Alzheimer's disease and other dementia-associated disorders. Clin Interv Aging 10, 1163-1172.

135.   Liu, C. C., Liu, C. C., Kanekiyo, T., Xu, H., and Bu, G. (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9, 106-118.

136.   Nordestgaard, L. T., Tybjærg-Hansen, A., Nordestgaard, B. G., and Frikke-Schmidt, R. (2015) Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease. Alzheimers Dement 11, 1430-1438.

137.   Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., and Buckley, N. J. (2019) Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. Front Neurosci 13, 164.

138.   Holler, C. J., Davis, P. R., Beckett, T. L., Platt, T. L., Webb, R. L., Head, E., and Murphy, M. P. (2014) Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer's disease brain and correlates with neurofibrillary tangle pathology. J Alzheimers Dis 42, 1221-1227.

139.   Andrew, R. J., De Rossi, P., Nguyen, P., Kowalski, H. R., Recupero, A. J., Guerbette, T., Krause, S. V., Rice, R. C., Laury-Kleintop, L., Wagner, S. L., et al. (2019) Reduction of the expression of the late-onset Alzheimer's disease (AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model. The Journal of biological chemistry 294, 4477-4487.

140.   Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., and Bohr, V. A. (2019) Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 15, 565-581.

141.   Bowl, M. R., and Dawson, S. J. (2019) Age-Related Hearing Loss. Cold Spring Harb. Perspect. Med. 9.

142.   Pelletier, A. L., Rojas-Roldan, L., and Coffin, J. (2016) Vision Loss in Older Adults. Am. Fam. Physician 94, 219-226.

143.   Alle, Q., Le Borgne, E., Milhavet, O., and Lemaitre, J. M. (2021) Reprogramming: Emerging Strategies to Rejuvenate Aging Cells and Tissues. International journal of molecular sciences 22.

144.   Zhao, J., and Huai, J. (2023) Role of primary aging hallmarks in Alzheimer´s disease. Theranostics 13, 197-230.

145.   Chakravarti, D., LaBella, K. A., and DePinho, R. A. (2021) Telomeres: history, health, and hallmarks of aging. Cell 184, 306-322.

146.   Coppedè, F., and Migliore, L. (2009) DNA damage and repair in Alzheimer's disease. Curr Alzheimer Res 6, 36-47.

147.   Lin, X., Kapoor, A., Gu, Y., Chow, M. J., Peng, J., Zhao, K., and Tang, D. (2020) Contributions of DNA Damage to Alzheimer's Disease. International journal of molecular sciences 21.

148.   Hou, Y., Song, H., Croteau, D. L., Akbari, M., and Bohr, V. A. (2017) Genome instability in Alzheimer disease. Mech Ageing Dev 161, 83-94.

149.   Schumacher, B., Pothof, J., Vijg, J., and Hoeijmakers, J. H. J. (2021) The central role of DNA damage in the ageing process. Nature 592, 695-703.

150.   Yousefzadeh, M., Henpita, C., Vyas, R., Soto-Palma, C., Robbins, P., and Niedernhofer, L. (2021) DNA damage-how and why we age? Elife 10.

151.   Rossiello, F., Herbig, U., Longhese, M. P., Fumagalli, M., and d'Adda di Fagagna, F. (2014) Irreparable telomeric DNA damage and persistent DDR signalling as a shared causative mechanism of cellular senescence and ageing. Curr Opin Genet Dev 26, 89-95.

152.   Victorelli, S., and Passos, J. F. (2017) Telomeres and Cell Senescence - Size Matters Not. EBioMedicine 21, 14-20.

153.   Anitha, A., Thanseem, I., Vasu, M. M., Viswambharan, V., and Poovathinal, S. A. (2019) Telomeres in neurological disorders. Adv Clin Chem 90, 81-132.

154.   Saul, D., and Kosinsky, R. L. (2021) Epigenetics of Aging and Aging-Associated Diseases. International journal of molecular sciences 22.

155.   Tecalco-Cruz, A. C., Ramírez-Jarquín, J. O., Alvarez-Sánchez, M. E., and Zepeda-Cervantes, J. (2020) Epigenetic basis of Alzheimer disease. World J Biol Chem 11, 62-75.

156.   Wei, X., Zhang, L., and Zeng, Y. (2020) DNA methylation in Alzheimer's disease: In brain and peripheral blood. Mech Ageing Dev 191, 111319.

157.   West, R. L., Lee, J. M., and Maroun, L. E. (1995) Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J Mol Neurosci 6, 141-146.

158.   Hernández-Ortega, K., Garcia-Esparcia, P., Gil, L., Lucas, J. J., and Ferrer, I. (2016) Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome. Brain Pathol 26, 593-605.

159.   Garcia-Esparcia, P., Sideris-Lampretsas, G., Hernandez-Ortega, K., Grau-Rivera, O., Sklaviadis, T., Gelpi, E., and Ferrer, I. (2017) Altered mechanisms of protein synthesis in frontal cortex in Alzheimer disease and a mouse model. Am J Neurodegener Dis 6, 15-25.

160.   Wang, X., Michaelis, M. L., and Michaelis, E. K. (2010) Functional genomics of brain aging and Alzheimer's disease: focus on selective neuronal vulnerability. Curr Genomics 11, 618-633.

161.   Wang, M., Roussos, P., McKenzie, A., Zhou, X., Kajiwara, Y., Brennand, K. J., De Luca, G. C., Crary, J. F., Casaccia, P., Buxbaum, J. D., et al. (2016) Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease. Genome Med 8, 104.

162.   SciFinder-n. https://scifinder-n.cas.org/ (accessed Apr 14, 2022).

163.   Bhatia, S., Rawal, R., Sharma, P., Singh, T., Singh, M., and Singh, V. (2022) Mitochondrial Dysfunction in Alzheimer's Disease: Opportunities for Drug Development. Curr Neuropharmacol 20, 675-692.

164.   Takuma, K., Yan, S. S., Stern, D. M., and Yamada, K. (2005) Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease. J Pharmacol Sci 97, 312-316.

165.   Picone, P., Nuzzo, D., Caruana, L., Scafidi, V., and Di Carlo, M. (2014) Mitochondrial dysfunction: different routes to Alzheimer's disease therapy. Oxid Med Cell Longev 2014, 780179.

166.   Weidling, I. W., and Swerdlow, R. H. (2020) Mitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis. Exp Neurol 330, 113321.

167.   Atamna, H., and Frey, W. H., 2nd (2007) Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 7, 297-310.

168.   Singulani, M. P., Pereira, C. P. M., Ferreira, A. F. F., Garcia, P. C., Ferrari, G. D., Alberici, L. C., and Britto, L. R. (2020) Impairment of PGC-1α-mediated mitochondrial biogenesis precedes mitochondrial dysfunction and Alzheimer's pathology in the 3xTg mouse model of Alzheimer's disease. Exp Gerontol 133, 110882.

169.   Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., and Gibson, G. E. (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57, 695-703.

170.   Chen, J. X., and Yan, S. D. (2007) Amyloid-beta-induced mitochondrial dysfunction. J Alzheimers Dis 12, 177-184.

171.   Perez Ortiz, J. M., and Swerdlow, R. H. (2019) Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities. Br J Pharmacol 176, 3489-3507.

172.   Zhang, Z., Yang, X., Song, Y.-Q., and Tu, J. (2021) Autophagy in Alzheimer's disease pathogenesis: Therapeutic potential and future perspectives. Ageing Research Reviews 72, 101464.

173.   Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., and Cuervo, A. M. (2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. Journal of Neuropathology & Experimental Neurology 64, 113-122.

174.   Heckmann, B. L., Teubner, B. J., Boada-Romero, E., Tummers, B., Guy, C., Fitzgerald, P., Mayer, U., Carding, S., Zakharenko, S. S., and Wileman, T. (2020) Noncanonical function of an autophagy protein prevents spontaneous Alzheimer's disease. Science advances 6, eabb9036.

175.   Lachance, V., Wang, Q., Sweet, E., Choi, I., Cai, C.-Z., Zhuang, X.-X., Zhang, Y., Jiang, J. L., Blitzer, R. D., and Bozdagi-Gunal, O. (2019) Autophagy protein NRBF2 has reduced expression in Alzheimer's brains and modulates memory and amyloid-beta homeostasis in mice. Molecular neurodegeneration 14, 1-13.

176.   Pickford, F., Masliah, E., Britschgi, M., Lucin, K., Narasimhan, R., Jaeger, P. A., Small, S., Spencer, B., Rockenstein, E., and Levine, B. (2008) The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid β accumulation in mice. The Journal of clinical investigation 118, 2190-2199.

177.   Drouin, E., and Drouin, G. (2017) The first report of Alzheimer's disease. The Lancet Neurology 16, 687.

178.   Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N., and Murtagh, F. R. (1995) An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 8, 429-431.

179.   Yin, F. (2023) Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise. The FEBS journal 290, 1420-1453.

180.   Gao, K., Wei, C., Zhu, J., Wang, X., Chen, G., Luo, Y., Zhang, D., Yue, W., and Yu, H. (2019) Exploring the Causal Pathway From Telomere Length to Alzheimer's Disease: An Update Mendelian Randomization Study. Front Psychiatry 10, 843.

181.   Herrmann, M., Pusceddu, I., März, W., and Herrmann, W. (2018) Telomere biology and age-related diseases. Clin Chem Lab Med 56, 1210-1222.

182.   Forero, D. A., González-Giraldo, Y., López-Quintero, C., Castro-Vega, L. J., Barreto, G. E., and Perry, G. (2016) Meta-analysis of Telomere Length in Alzheimer's Disease. J Gerontol A Biol Sci Med Sci 71, 1069-1073.

183.   Eitan, E., Hutchison, E. R., and Mattson, M. P. (2014) Telomere shortening in neurological disorders: an abundance of unanswered questions. Trends Neurosci 37, 256-263.

184.   Scarabino, D., Broggio, E., Gambina, G., and Corbo, R. M. (2017) Leukocyte telomere length in mild cognitive impairment and Alzheimer's disease patients. Exp Gerontol 98, 143-147.

185.   Mahoney, E. R., Dumitrescu, L., Seto, M., Nudelman, K. N. H., Buckley, R. F., Gifford, K. A., Saykin, A. J., Jefferson, A. J., and Hohman, T. J. (2019) Telomere length associations with cognition depend on Alzheimer's disease biomarkers. Alzheimers Dement (N Y) 5, 883-890.

186.   Fluegge, K. (2019) A model of lipid dysregulation and altered nutrient status in Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 5, 139-145.

187.   Liu, G. Y., and Sabatini, D. M. (2020) mTOR at the nexus of nutrition, growth, ageing and disease. Nature reviews Molecular cell biology 21, 183-203.

188.   Shafei, M. A., Harris, M., and Conway, M. E. (2017) Divergent metabolic regulation of autophagy and mTORC1—early events in Alzheimer's disease? Frontiers in aging neuroscience 9, 173.

189.   Fidaleo, M., Cavallucci, V., and Pani, G. (2017) Nutrients, neurogenesis and brain ageing: From disease mechanisms to therapeutic opportunities. Biochemical pharmacology 141, 63-76.

190.   B Jahrling, J., and Laberge, R.-M. (2015) Age-related neurodegeneration prevention through mTOR inhibition: potential mechanisms and remaining questions. Current topics in medicinal chemistry 15, 2139-2151.

191.   Rena, G., Hardie, D. G., and Pearson, E. R. (2017) The mechanisms of action of metformin. Diabetologia 60, 1577-1585.

192.   Zhao, Z., Liu, Y., Ruan, S., and Hu, Y. (2023) Current Anti-Amyloid-β Therapy for Alzheimer's Disease Treatment: From Clinical Research to Nanomedicine. Int J Nanomedicine 18, 7825-7845.

193.   Anti-Amyloid Monoclonal Antibody Drugs Continue to Show Promise Treating Alzheimer Disease. https://www.pharmacytimes.com/view/anti-amyloid-monoclonal-antibody-drugs-continue-to-show-promise-treating-alzheimer-disease (accessed Feb 29, 2024).

194.   Davey, M. Alzheimer's 'breakthrough' stalls: why a much-hyped drug is facing approval delays. https://www.theguardian.com/society/2024/mar/24/alzheimers-breakthrough-drugs-medicine-donanemab-aducanumab-lecanemab (accessed Mar 25, 2024).

195.   Scott, I. A. (2024) Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent 'positive' trials. Age and Ageing 53.

196.   FDA Grants Accelerated Approval for Alzheimer's Drug. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug (accessed Feb 28, 2024).

197.   Biogen to Realign Resources for Alzheimer's Disease Franchise. https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise#:~:text=The%20company%20will%20discontinue%20the,any%20safety%20or%20efficacy%20concerns. (accessed Feb 28, 2024).

198.   FDA Grants Accelerated Approval for Alzheimer's Disease Treatment. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment#:~:text=Today%2C%20the%20U.S.%20Food%20and,fundamental%20pathophysiology%20of%20the%20disease. (accessed Feb 28, 2024).

199.   Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330, 512-527.

200.   LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE. https://investors.biogen.com/news-releases/news-release-details/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary (accessed May 29, 2024).

201.   Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) Donanemab in Early Alzheimer's Disease. New England Journal of Medicine 384, 1691-1704.

202.   Long, J. M., and Holtzman, D. M. (2019) Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell 179, 312-339.

203.   U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab. https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-convene-advisory-committee (accessed May 29, 2024).

204.   Alzheimer's: Drugs help manage symptoms. https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048103 (accessed Feb 28, 2024).

205.   Treatment Alzheimer's disease. https://www.nhs.uk/conditions/alzheimers-disease/treatment/ (accessed Feb 28, 2024).

206.   Medications for Alzheimer's Disease. https://stanfordhealthcare.org/medical-conditions/brain-and-nerves/alzheimers-disease/treatments/medications.html (accessed Feb 28, 2024).

207.   Grabowska, M. E., Huang, A., Wen, Z., Li, B., and Wei, W. Q. (2023) Drug repurposing for Alzheimer's disease from 2012-2022-a 10-year literature review. Front Pharmacol 14, 1257700.

208.   Advanced Drug Repurposing and Combination Therapy Development. https://www.nia.nih.gov/10-years-alzheimers-disease-and-related-dementias-research/advanced-drug-repurposing (accessed Mar 11, 2024).

209.   Das, A. K. K., Sharma, D., and Sharma, L. (2021) Drug repurposing strategy for treating Alzheimer's disease. Alzheimer's & Dementia 17, e058503.

210.   Bauzon, J., Lee, G., and Cummings, J. (2020) Repurposed agents in the Alzheimer's disease drug development pipeline. Alzheimer's Research & Therapy 12, 98.

211.   Anderson, C., Bucholc, M., McClean, P. L., and Zhang, S.-D. (2024) The Potential of a Stratified Approach to Drug Repurposing in Alzheimer's Disease. Biomolecules 14, 11.

212.   Norins, L. C. (2021) Repurposing Licensed Drugs for Use Against Alzheimer's Disease. J Alzheimers Dis 81, 921-932.

213.   Xu, Y., Kong, J., and Hu, P. (2021) Computational Drug Repurposing for Alzheimer's Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies. Frontiers in Pharmacology 12.

214.   Rodriguez, S., Hug, C., Todorov, P., Moret, N., Boswell, S. A., Evans, K., Zhou, G., Johnson, N. T., Hyman, B. T., Sorger, P. K., et al. (2021) Machine learning identifies candidates for drug repurposing in Alzheimer's disease. Nature Communications 12, 1033.

215.   Yan, C., Grabowska, M. E., Dickson, A. L., Li, B., Wen, Z., Roden, D. M., Michael Stein, C., Embí, P. J., Peterson, J. F., Feng, Q., et al. (2024) Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation. npj Digital Medicine 7, 46.

216.   Savva, K., Zachariou, M., Bourdakou, M. M., Dietis, N., and Spyrou, G. M. (2022) Network-based stage-specific drug repurposing for Alzheimer's disease. Computational and Structural Biotechnology Journal 20, 1427-1438.

217.   Ballard, C. A Placebo Controlled, Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease, Nested within a Multi-Arm Phase 2 Clinical Trial Platform. https://www.alzdiscovery.org/research-and-grants/portfolio-details/21208491 (accessed Mar 14, 2024).

218.   Kumar, N., Gahlawat, A., Kumar, R. N., Singh, Y. P., Modi, G., and Garg, P. (2022) Drug repurposing for Alzheimer's disease: in silico and in vitro investigation of FDA-approved drugs as acetylcholinesterase inhibitors. Journal of Biomolecular Structure and Dynamics 40, 2878-2892.

219.   Lee, S. Y., Song, M.-Y., Kim, D., Park, D. K., and Kim, Y. H. (2020) A proteotranscriptomic-based computational drug-repositioning method for Alzheimer's disease. Frontiers in pharmacology 10, 502162.

220.   Mielke, M. M., and Zandi, P. P. (2006) Hematologic risk factors of vascular disease and their relation to dementia. Dement Geriatr Cogn Disord 21, 335-352.

221. Wolters, F. J., Zonneveld, H. I., Licher, S., Cremers, L. G. M., Group, o. b. o. t. H. B. C. C. R., Ikram, M. K., Koudstaal, P. J., Vernooij, M. W., and Ikram, M. A. (2019) Hemoglobin and anemia in relation to dementia risk and accompanying changes on brain MRI. Neurology 93, e917-e926.

222. Luo, J., Thomassen, J. Q., Nordestgaard, B. G., Tybjærg-Hansen, A., and Frikke-Schmidt, R. (2022) Blood Leukocyte Counts in Alzheimer Disease. JAMA Network Open 5, e2235648-e2235648.

223. Gambineri, A., and Pelusi, C. (2019) Sex hormones, obesity and type 2 diabetes: is there a link? Endocr Connect 8, R1-r9.

224. Moudgil, K. D., and Venkatesha, S. H. (2022) The Anti-Inflammatory and Immunomodulatory Activities of Natural Products to Control Autoimmune Inflammation. International journal of molecular sciences 24.

225. Oliver, B., Jackson, E., and Soliman, H., Chapter 17 - Immunostimulators and Immunomodulators in Cancer Treatment. In *Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies*, Singh, M.; Salnikova, M., Eds. Academic Press: San Diego, 2015; pp 411-431.

226. DeMarshall, C. A., Viviano, J., Emrani, S., Thayasivam, U., Godsey, G. A., Sarkar, A., Belinka, B., Libon, D. J., and Nagele, R. G. (2023) Early Detection of Alzheimer's Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers. J Alzheimers Dis 92, 1077-1091.

227. Alzheimer's Disease Neuroimaging Initiative. https://adni.loni.usc.edu/ (accessed feb 29, 2024).

228. The Global Alzheimer's Association Interactive Network. https://www.gaain.org/ (accessed Feb 29, 2024).

TOC graphic